

HERMES DECLARATION

EXHIBIT 15 – PART 7 OF 8

United States Patent [19]

Pinchuk et al.

US05116360A

[11] Patent Number: 5,116,360

[45] Date of Patent: May 26, 1992

[54] MESH COMPOSITE GRAFT

[75] Inventors: Leonard Pinchuk; John B. Martin, Jr., both of Miami; Bruce A. Weber, Pembroke Pines, all of Fla.

[73] Assignee: Corvita Corporation, Miami, Fla.

[21] Appl. No.: 634,425

[22] Filed: Dec. 27, 1990

[51] Int. Cl. 3 A61F 2/06

[52] U.S. Cl. 623/1; 623/11; 623/12

[58] Field of Search 623/12, 1

[56] References Cited

U.S. PATENT DOCUMENTS

4,475,972 10/1984 Wong .
4,969,896 11/1990 Shors 623/1

Primary Examiner—David Isabella

Assistant Examiner—Debra S. Brittingham

Attorney, Agent, or Firm—Lockwood, Alex, FitzGibbon & Cummings

[57] ABSTRACT

A mesh composite graft including an inner component, an outer component formed from strands of durable material, such as polyethylene terephthalate, and an intermediate component made from strands of biocompatible synthetic material having a melting point less than that of the durable material from which the outer component is formed and less than that of the biocompatible synthetic material from which the inner component of the graft is formed. By heating the graft to a temperature greater than the melting point of the material from which the intermediate component is formed but less than the melting point of the outer component material and less than the melting point of the material from which the inner component is formed, the components are bound by the melted intermediate component to provide a totally porous, compliant composite graft reinforced by the outer component.

19 Claims, 1 Drawing Sheet




FIG. 1





FIG. 2



MESH COMPOSITE GRAFT

BACKGROUND AND DESCRIPTION OF THE INVENTION

The present invention generally relates to implantable prostheses and the like and to methods for making same. More particularly, the invention relates to a graft, such as a vascular graft or AV-shunt, having a compliant porous inner component and a compliant porous load-bearing outer component, bound together by a porous intermediate component that is made of material having a melting point lower than that of the materials from which the inner and outer components are made. With the outer component bound by the intermediate component to the inner component, a porous, yet strengthened integral graft results.

Blood vessels are not straight, rigid tubes but elastic conduits made of a variety of materials and having a compliance that varies with functional considerations. For example, the venous system functions, in part, as the blood reservoir for the body. In order to be able to respond to a larger volume of blood sent into the system because of, for example, a change in arterial blood pressure, the vessels of the venous system must be sufficiently compliant so that they can distend. The arterial system functions as the body's pressure reservoir. In order to avoid the wide swings in the blood pressure and flow that are possible with every contraction and relaxation of the heart, yet be able to maintain sufficient blood pressure so that blood can be pushed into all regions of the body, including through the small-diameter arterioles and the microcirculatory bed, the arteries must have sufficient compliant strength to elastically expand and recoil without the marked distension of the venous system.

Conventional grafts, however, are generally made of materials and in shapes that provide a structure whose compliance is markedly different from that of the walls 40 of the vessel to which they may be attached. Grafts having walls less compliant than that of the host vessel walls are problematic in that conditions, such as intimal hyperplasia and stenotic narrowing, may develop. Grafts with walls having greater compliance than that 45 of the vessel to which the graft is attached are problematic in that a portion of the graft wall may balloon—that is, develop an aneurysm—after implantation.

Other known grafts, while they may be compliant, may not necessarily be made from biocompatible materials. The implantation of a graft made from such material may prompt a thrombogenic or immunological response with the resultant deleterious formation of microthrombi or microocclusions in and around the graft. Other grafts are made from generally non-porous materials, that, accordingly, do not facilitate the ingrowth of cells and tissue within the graft. The full incorporation of the graft into the surrounding host tissue is thereby frustrated. Still other conventional grafts are made from microporous textiles that require 55 preclotting of the vessel wall with blood to prevent leakage of blood at implantation.

A demand therefore is present for an integral graft made from biocompatible materials and having a structure that has compliant strength similar to that of natural tissue but that is sufficiently porous so that the graft may become incorporated into the host tissue yet not leak blood. The present invention satisfies the demand.

The present invention includes a three component system, an inner component, an intermediate component, and an outer component. While the components may be made from materials having generally different melting points and different mechanical properties, at a minimum the inner component and outer component are made from a material or materials having a melting temperature higher than the material from which the intermediate component is made. More specifically, the inner component is porous and is made from a biocompatible synthetic material, preferably a polyurethane composition made with an aromatic polycarbonate intermediate, having a melting point that is, at a minimum, in excess of the melting point of the composition from which the intermediate component is formed (further discussed below).

There are many methods by which the inner component may be made, such as the many known methods used to produce porous compliant vascular prostheses. 20 One such method is termed phase inversion or separation, which involves dissolving a urethane in a solvent, such as dimethyl acetamide (DMA), forming a coat on a mandrel—such as by dipping the mandrel into the dissolved urethane—and then immersing the urethane coating in a solution such as water by which DMA may be dissolved, but not urethane, thereby causing the urethane to bead-up and form a porous matrix.

Another method by which the inner component may be formed is termed particle elution. The method utilizes water soluble particles such as salt (NaCl, MgCl₂, CaCO₃, etc.) polymers, such as polyvinylpyrrolidone, sugars etc. The particles are mixed or blended into a urethane composition, and after forming a graft from the mixture such as by dip coating or extruding the particle filled plastic, the particle is eluted out with a suitable solvent.

Additional methods include replamineform, that involves the dissolution of a matrix, such as that of a sea 30 urchin, out of the urethane with hydrochloric acid, spray techniques where filaments or beads of urethane are sprayed onto a mandrel to produce a porous vascular graft, and electrostatic deposition of urethane fibers from solution.

However, the porous vascular graft preferred in this invention is prepared according to the method detailed in U.S. Pat. No. 4,475,972 to Wong. This patent is incorporated herein by reference. An antioxidant may be added to further prevent degradation of the fibers drawn of the material from which the inner component is made.

Regardless of the nature and method of manufacturing the porous inner component, the intermediate component is comprised of one or more layers of a biocompatible synthetic material, preferably a polyurethane material, having a melting point lower than the melting point of the material from which the inner component is formed and lower than the melting point of the material from which the outer component is made.

The outer component comprises a mesh network made of strands, fibers, beads or expanded versions of a durable material such as a composition of fluorocarbons, such as expanded polytetrafluoroethylene ("ePTFE")—commonly termed Teflon—or stable polyesters, such as preferably polyethylene terephthalate ("PET")—commonly termed Dacron. This material is preferably warp-knitted in a tricot or double tricot pattern and shaped in a tubular configuration. It can also be appreciated that the outer component can be woven, braided,

weft-knitted and the like with loose fibers, textured fibers and the like to provide increased compliance. With the three components in place, a composite graft according to the present invention is formed by heating the structure to a temperature at or above the melting point of the material from which the intermediate component is formed but below the melting temperature or temperatures of the material from which the outer component is formed and of the material from which the inner component is formed. In this temperature range, the intermediate component may melt without the melting of either the inner component and the outer component, thereby mechanically bonding the inner component to the outer component.

The multi-component system of the present invention provides a number of advantages over conventional grafts. The use of a durable material, such as PET or ePTFE, from which the outer component may be formed is advantageous because of the known strength that such material has in the body. Devices made from PET or ePTFE when implanted in the body are known to maintain their integrity for some three decades. Further advantageously, it has been found that a graft—made according to the present invention and in which PET is used to form the outer component—has a burst strength and a tensile strength that is some two times greater than that of a conventional graft. Such strength prevents the dilation of the vessel in response to, for example, an increase in blood flow and/or pressure, creep relaxation of the urethane, biodegradation of the urethane, plasticization of the urethane, etc. Decreases in the strength of PET that may occur after implantation due, for example, to the absorption of water after implantation, are minimal as Dacron has a low water absorption ability.

The use of a knitted pattern according to which the durable strands of the outer component may be configured is advantageous due to the increased compliance such a pattern provides. As stated above, a durable material such as PET is recognized as a strong yet not necessarily compliant material. However, by knitting the strands from which the outer component is formed into a network, a compliant reinforcing outer component is formed. The use of such a material from which to form the outer component in the three component system of the present invention advantageously provides a strengthened, yet compliant graft.

The winding of strands of synthetic material, such as polyurethane over a mandrel to form an inner component is further advantageous because of the resultant porosity of the component. While the intermediate component may be made porous, for example, by painting synthetic material over the inner component and utilizing the phase inversion method or the particle elution method to form a porous matrix, preferably the intermediate component is formed by winding strands of synthetic material, such as polyurethane over the inner component, to provide a highly porous network. Utilizing strands of PET configured in a knitted pattern to form the outer reinforcement component further provides a porous network. Advantageously, by combining these individually porous components together in a composite graft, a totally porous integral graft results. Porosity is an advantage in medical devices, such as vascular grafts, because an open structure allows vascular fluid to infiltrate and communicate to and from the surrounding tissue and the interior of the graft and allows the ingrowth of tissue to occur within the

graft. Accordingly, the device becomes better incorporated into the surrounding tissue, thereby further securing the device within the implantation site.

Uniting the three components into a single composite graft advantageously facilitates the use of the device. The graft may be implanted without the need for any assembly immediately prior to use. The graft may be also cut and/or sutured as a unit without the need for the separate cutting and/or suturing of each component. Methods for cutting the composite graft include scalpel, scissors, hot wires, shaped blades, and the like. The speed with which the graft may be implanted is a particularly distinct advantage since the device is implanted only when a patient is undergoing surgery.

The use of a polycarbonate intermediate rather than, for example, a polyether urethane to make the polyurethane material from which the inner component is preferably made is advantageous as the resultant inner component better resists degradation. The resistance to degradation is further aided by the addition of antioxidant to the material from which the inner component is formed.

It is, accordingly, a general object of the present invention to provide an improved graft.

Another object of the present invention is to provide an integral improved graft made from a composite of layers of synthetic materials.

It is also an object of the present invention to provide a graft that is totally porous thereby facilitating the incorporation of the graft into the site of implantation.

An additional object of the present invention is to provide an improved graft having an outer component which strengthens the device without significantly impairing the overall compliance of the graft.

These and other objects, features and advantages of this invention will be clearly understood and explained with reference to the accompanying drawings and through a consideration of the following detailed description.

BRIEF DESCRIPTION OF THE DRAWINGS

In the course of this description, reference will be made to the attached drawings, wherein:

FIG. 1 is a perspective view illustrating an embodiment of a composite vascular graft according to the present invention with an outer component of knitted durable material positioned over and bound by an intermediate component to an inner component; and

FIG. 2 is a cross sectional view of the composite vascular graft according to the present invention illustrated in FIG. 1.

DESCRIPTION OF THE PARTICULAR EMBODIMENTS

The present invention is a composite vascular graft—generally designated as 21 in FIGS. 1 and 2—comprised of an inner component 31, an intermediate component 41, and an outer component 61. The inner component will be described first.

Inner component 31 is fabricated from a biocompatible synthetic material, preferably polyurethane, having a melting temperature that is, at a minimum, greater than the melting temperature of the material from which the intermediate component is formed. Preferably, in those embodiments in which the inner component 31 is formed from polyurethane, it is made with an aromatic polycarbonate urethane. Polycarbonate urethanes are preferred over polyether urethanes due to

their superior biostability. The aromatic polycarbonate urethanes have melting points in the range of 150° C. to 230° C. This is in contrast to some aliphatic polycarbonate urethanes that have melting points between 90° C. and 130° C. It can also be appreciated that the inner member may be composed of non-urethane materials such as silicone rubber, polyolefins, fluoroelastomers, ePTFE, and the like. An antioxidant, such as Irganox 1010, may be added to the inner member to further prevent degradation of the strands from which the inner component is formed. The melting temperature of the material from which the inner component is preferably formed exceeds 150° C.

The methods by which the inner component 31 may be fabricated include those disclosed in U.S. Pat. No. 4,475,972 to Wong. According to a fabrication method taught in the Wong patent, termed "solution processing", the inner component material is dissolved in a solvent and forced out of one or more orifices to form one or more continuous fibers. The fibers are drawn directly onto a rotating mandrel. As the distributor or spinnerette reciprocates along the mandrel, non-woven strands are layered on top of each other to form porous, non-woven network of criss-crossing strands.

The intermediate layer 41 is formed of a biocompatible synthetic material, such as a polyolefin, a silicone thermoplastic material, etc., or preferably a polyurethane material having a melting temperature less than that of the materials from which the inner and outer components are formed. The intermediate layer can be drawn in the manner described in the Wong patent so that at least one fibrous layer is laid over the inner component 31 to form a porous intermediate layer. This intermediate layer can be spun from solution as described in the Wong patent or can be simply wound onto the inner layer from a spool of the biocompatible low melting point material. Alternatively, phase inversion or particle elution methods may be used to form a porous intermediate component. Examples of suitable low melting point biocompatible materials include the aliphatic polycarbonate or polyether urethanes with melting points of 90° C. to 130° C. The resultant porous, non-woven network of strands forming the intermediate component 41, as drawn over the inner component 31 form a unit 51 which facilitates the transmission of fluid.

Mesh 61, composed of strands of durable material, such as PET or ePTFE, knitted or woven in a generally elongated cylindrical shape and whose inner surface 63 is of a diameter equal to or slightly larger than the diameter of the outer surface 45 of the intermediate component 41, is fitted over the intermediate component 41. To provide compliance to the mesh network of strands from which the outer component is formed, the strands are configured preferably in a knitted pattern. Tricot or double tricot warp knit patterns are preferred. Double tricot patterns are further advantageous because they provide greater depth to the outer component 61 and thereby facilitate the acceptance of and retention of sutures and tissue ingrowth through the graft 21. Tricot or double tricot warp patterns are further advantageous in that they are generally more interlocking than other patterns and therefore resist "running". Other acceptable patterns according to which the strands of the outer component 61 may be formed include jersey or double jersey patterns, woven or braided and multiple layers of the above. Also, the

fibers comprising the outer structure may be textured or non-textured and be of a variety of deniers.

The outer component 61 as positioned over the inner component and intermediate component is heated to a temperature equal to or greater than the temperature at which the material from which the intermediate component 41 is formed melts but less than the temperature and/or temperatures at which the material or materials from which the outer component and from which the inner component 31 is formed melts. When the inner component 31 is formed from the preferred material described above, the components are heated to a temperature less than 150° C. but greater than the temperature at which the material from which the intermediate component 41 is formed melts, such as 110° C. By maintaining the three components at such a temperature for a period of time, such as ten minutes, the intermediate component melts thereby securing the outer component 61 and the inner component 31 to each other. To further ensure the secure full engagement of the outer component 61 by the melted intermediate component 41, the outer component 61 may be forcefully pressed into the intermediate component 41 during the heating step such as mechanically and/or with or under pressure. After heating, the united three components are cooled thereby providing an integral mesh composite graft 21.

A mesh composite graft 21 according to the present invention is totally porous and compliant, yet advantageously includes a load bearing component, the outer component 61, which adds strength to the graft and prevents the failure of the graft even in response to greater fluid volume pressures from within, creep relaxation of the inner member and possible biodegradation effects of the inner member.

The advantageous compliance of the composite graft may be adjusted by varying the number of strands from which the inner component and the intermediate component 41 are formed. The compliance of the composite graft 21 may be adjusted also by varying the materials from which the inner component 31 and the intermediate component 41 are formed while maintaining the relationship that the intermediate component 41 must melt at a lower temperature than the materials from which the outer component and the material from which inner component 31 is formed. The compliance of the mesh composite graft 21 may be adjusted further by adjusting the angle at which the strands of the inner component 31 and/or the strands of the outer component 61 are laid down—a higher angle provides a less compliant component and thereby a less compliant graft.

The compliance may be adjusted even further by altering the knitting parameters, such as courses and wales per inch, the stitch density, the fiber denier, the number of strands per filament, the composition of the fibers and filaments such as a mixture of PET and Spandex compositions and whether the outer member is knitted, woven or braided.

The advantageous overall porosity of the graft 21 may be adjusted also in a number of ways. In addition to varying the size and number of the strands from which the inner component 31 and intermediate component 41 are formed, the strands of each component may be drawn at different angles to provide decreased pore size and resultant decreased porosity. Similarly, the porosity of the outer component 61, and thereby the porosity of the composite graft 21 may be varied by varying the

size and/or number of the strands and stitch density used to make the outer component mesh.

It can also be appreciated that the outer component need not be a tube formed specifically for this purpose from materials as above but can also be made from a vascular graft preformed from a porous matrix material such as ePTFE. One such graft is manufactured by W. L. Gore and marketed as a Gore-Tex graft. The ePTFE graft may be sheathed over the previously described inner and intermediate components and heat fused into a similar composite graft described in this document. Similarly, the inner members may be a Gore-Tex graft, the intermediate component, a heat fusible thermoplastic, and the outer component, a Dacron knit.

Regardless of the configuration of the inner, intermediate and outer components of the graft, i.e. be it spun, salt eluted, phase inverted, wound with an outer PET mesh, or in which an ePTFE configuration is utilized, the resultant composite graft 21 as formed may be implanted in vascular locations and retained in place through conventional methods, such as suturing. The preferred use of PET, knitted in a preferred tricot or double tricot pattern, from which to make the outer component 61 of the graft 21 provides a graft having a greater thickness than grafts without such a load bearing component. The outer component 61 facilitates the greater retention of the sutures within the graft.

It will be understood that the embodiments of the present invention as described are illustrative of some of the applications of the principles of the present invention. Modifications may be made by those skilled in the art without departure from the spirit and scope of the invention.

We claim:

1. A composite graft for implantation within a host, comprising:
an inner component made from wound, criss-crossing layers of fibers of a first biocompatible synthetic material and shaped to form a porous generally elongated cylindrical shape having a lumen through which blood may flow, said inner component having an outer surface;
an intermediate compliant bonding component made from wound, criss-crossing layers of fiber of a second biocompatible synthetic material, said second material having a melting point lower than the melting point of said first material and lower than the melting point of polyethylene terephthalate, said intermediate component positioned generally over and substantially covering said outer surface of said inner component, said intermediate component being porous and having an outer surface;
said intermediate component as positioned over said outer surface of the inner component forming a fluid transmission unit;
an outer component made from a mesh formed from strands of matrices of durable material, said strands or matrices preformed in a generally elongated cylindrical shape having a lumen therethrough and a diameter which is approximately equal to the outside diameter of said intermediate component, said outer component is positioned over and substantially covering said outer surface of the intermediate component; wherein each said outer component and said inner component is bonded to said intermediate component when each of the compo-

nents is heated to a temperature less than the melting temperature of said first material and said durable material thereby securing said components to each other to form a totally porous mesh composite graft.

2. The mesh composite graft according to claim 1, wherein said biocompatible synthetic material from which said inner component is made is polyurethane

3. The mesh composite graft according to claim 2, wherein said polyurethane is made with a polycarbonate intermediate.

4. The mesh composite graft according to claim 2, wherein said polyurethane is made with an aromatic polycarbonate urethane.

5. The mesh composite graft according to claim 1, wherein said biocompatible synthetic material from which said inner component is made is silicone rubber.

6. The mesh composite graft according to claim 1, wherein said biocompatible synthetic material from which said inner component is made is a polyolefin.

7. The mesh composite graft according to claim 1, wherein said biocompatible synthetic material from which said inner component is made is a fluoroelastomer.

8. The mesh composite graft according to claim 3, wherein said polyurethane includes an antioxidant to prevent degradation of said inner component.

9. The mesh composite graft according to claim 1, wherein said biocompatible synthetic material from which said intermediate component is made is polyurethane.

10. The mesh composite graft according to claim 9, wherein said polyurethane is an aliphatic polycarbonate.

11. The mesh composite graft according to claim 1, wherein said biocompatible synthetic material from which said intermediate component is made is a polyolefin.

12. The mesh composite graft according to claim 1, wherein said biocompatible synthetic material from which said intermediate component is made is a silicon thermoplastic material.

13. The mesh composite graft according to claim 1, wherein said outer component is further secured to said fluid transmission unit by pressing said outer component into said intermediate component during heating.

14. The mesh composite graft according to claim 1, wherein said mesh is formed by knitting said strands of polyethylene terephthalate.

15. The mesh composite graft according to claim 1, wherein said mesh is formed by knitting said strands of polyethylene terephthalate in a tricot pattern.

16. The mesh composite graft according to claim 1, wherein said mesh is formed by knitting said strands of polyethylene terephthalate in a double tricot pattern.

17. The mesh composite graft according to claim 2, wherein said mesh is formed from strands of expanded polytetrafluoroethylene.

18. The mesh composite graft according to claim 2, wherein said mesh is preformed from strands of polytetrafluoroethylene.

19. The mesh composite graft according to claim 2, wherein said mesh is a preformed porous matrix of expanded polytetrafluoroethylene.

* * * *

701/157
BTM-28IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: Alastair W. Hunter, et al.

Serial No.: 838,511 Art Unit: 1504

Filed : February 19, 1992 Examiner: C. Raimund

For : STERILIZED HETEROGENEOUS BRAIDS

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner of Patents and Trademarks, Washington, D.C. 20231 on

December 2, 1992

(Date of Deposit)

Matthew S. Goodwin

Name of applicant, assignee, or Registered Representative

Matthew S. Goodwin

Dec 4 10 1992

December 2, 1992

(Date of Signature)

CPTM 1500

Hon. Commissioner of Patents
and Trademarks
Washington, D.C. 20231

AMENDMENT

Dear Sir:

Please reconsider the above-identified application in view of the following remarks. These remarks are subdivided into a discussion of the claimed invention, and an analysis of the rejection, to facilitate an understanding of the significant differences between the cited art and the claimed invention.

Discussion of the Invention

A proper understanding of the invention is critical for appreciating the dissimilarities between the invention and the teachings of the cited references.

In a broad sense, the invention is a braided suture which contains dissimilar filaments of first and second fiber-forming materials. However, the proper characterization of the claimed suture goes far beyond this simple description.

The braided suture is made up of multifilament yarns. A multifilament yarn is a bundle of individual filaments which are integrated to form a single unit, that is, an individual multifilament yarn. The braided suture has a first and second set of these multifilament yarns in a braided construction. Each of the filaments of the first set of yarns is composed of a first fiber-forming material. Similarly, each of the filaments of the second set of yarns is composed of a second fiber-forming material.

The importance of the construction of the first and second set of yarns cannot be diminished. The braided construction is not accurately characterized by simply referring to a suture with filaments of dissimilar fiber-forming materials in a braided construction. Rather, filaments of a first fiber-forming material must be bundled to prepare a first set of multifilament yarns, and filaments of the second fiber-forming material must also be bundled to prepared the second set of multifilament yarns.

Once an understanding of the composition and construction of each set of first and second yarns is achieved, the importance of a further characterization of the braid construction can now be understood and appreciated. One yarn from the first set of yarns is in direct intertwining contact with a yarn from the second set of yarns. This limitation does not simply mean that the dissimilar filaments are fabricated into a braided construction, that is, dissimilar filaments are in "intertwining contact". Rather it is a multifilament yarn which is in direct intertwining contact with another multifilament yarn. Again, it is important to emphasize here that the multifilament yarns are integrated bundles of individual filaments, and it is this integrated bundle of filaments of a first fiber-forming material which is in direct intertwining

contact with another integrated bundle of individual filaments of a second fiber-forming material.

One way to accurately characterize the braided suture of this invention is to refer to it as a structured mechanical blend of dissimilar fiber-forming materials. The fiber-forming materials are first arranged into integrated bundles to form multifilament yarns and then these multifilament yarns are further arranged so that at least one yarn from the first set of yarns directly intertwines with a multifilament yarn from the second set of yarns. This can be contrasted with a random, braided construction where filaments of dissimilar fiber-forming materials are randomly braided with one another to form a braided suture.

The heterogeneous braids of this invention exhibit truly outstanding and surprising properties. The integrity of the braid and therefore its properties is due entirely to the mechanical interlocking or weaving of the individual multifilament yarns (see the specification at page 4, lines 30-33). In the preferred embodiment, each yarn from the first set of multifilament yarns is in direct intertwining contact with a yarn of the second set to achieve the maximum degree of mechanical blending of the dissimilar multifilament yarns (see the specification at page 6, lines 28-31, and claim 15). In this way, yarn compatibility can be further enhanced and the overall physical and biological properties of the heterogeneous braid can be further improved as well.

What is truly surprising with respect to the claimed heterogeneous braid construction is that certain bulk properties of the claimed braid are better than what one skilled in the art would expect. A skilled artisan would expect the properties of the braid to simply follow the "Rule of Mixtures", where the bulk property

measured would be estimated to be a weighted average of its component properties. Upon studying the Examples in the specification, it will be noted that the bending rigidity of the heterogeneous braids in Examples 1 and 2 do not follow the Rule of Mixtures, but surprisingly show an enhanced bending rigidity relative to the weighted average of their filament components. This behavior is not achieved when dissimilar individual filaments are randomly braided to form the braided suture.

In setting forth the claimed invention, the heterogeneous braid does not encompass braided sutures with randomly braided individual filaments, as described in detail above. Further, the claimed heterogeneous braid could not be construed to cover known braids which have a core of longitudinally extending yarns composed of filaments of a first fiber-forming material, and a sheath of braided yarns composed of a second set of filaments of a dissimilar fiber-forming material. This braid construction does not fall within the scope of the claimed braid because these sheath yarns are not in direct intertwining contact with any of the core yarns. In other words, none of the sheath yarns are braided about a core yarn, but simply shroud the core yarns to form the sheath construction.

Analysis of the Rejection

1. Claims 21 and 23 were rejected under 35 USC §102(b) as being clearly anticipated by Doddi et al. ("Doddi"). Doddi does not anticipate the claimed suture, and therefore this rejection should be withdrawn.

The Examiner has correctly pointed out that Doddi does indeed disclose a surgical suture comprising filaments of two different polymers in a braided configuration (column 9, lines 47-56).

However, as discussed in detail above, more is required to meet the limitations of the claimed suture than just a disclosure concerning filaments of two different polymers in a braided configuration. Doddi teaches nothing more than braiding individual filaments, and fails to provide any guidance as to how that braiding should be carried out. Therefore, one skilled in the art would be lead to believe that what Doddi had in mind was to simply braid individual filaments in a randomized fashion to fabricate a multifilament suture. It is important enough, however, to reemphasize again that the claimed braid requires the bundling of individual filaments into an integrated unit to form a multifilament yarn. It is this multifilament yarn which directly intertwines with another multifilament yarn to form Applicants' braid construction.

Since Doddi only teaches randomly braiding filaments of dissimilar fiber-forming materials, it does not anticipate the claimed braided suture. Doddi simply fails to enable one skilled in the art to construct a braided suture in the manner set forth by Applicants, and it is axiomatic that a reference which lacks enablement is deficient as a reference to anticipate a claimed invention. Accordingly, it is respectfully requested that the rejection of claims 21 and 23 under 35 USC §102(b) as being clearly anticipated by Doddi be withdrawn.

2. Claims 22 and 24 were rejected under 35 USC §103 as being unpatentable over Kaplan et al. ("Kaplan") taken with Doddi. The Examiner asserts it would have been obvious to substitute PET and PTFE fibers of Doddi for the filaments of Kaplan to arrive at Applicants' claimed suture. Applicants respectfully traverse this rejection for the reasons given below.

The Examiner correctly points out that Kaplan discloses a ligament prosthesis made from a core component and a braided sheath component as illustrated in Figures 3 and 4, and discussed at column 8, line 65, through column 9, line 34. However, Kaplan suffers from the same deficiencies as does Doddi, and therefore fails to teach or suggest the claimed braided suture.

Firstly, the Examiner has made specific reference to the Kaplan specification regarding the makeup of the core components and the sheath yarn component. The only component which has a braided construction is the sheath yarn component. It is clear from Figure 3 of Kaplan that none of the sheath yarn components are in direct intertwining contact with the core component. In other words, the sheath yarn component is a true "sheath" which shrouds the core but is not in any way integrally braided with the core. Therefore, since the core is not in a braided construction, its composition is irrelevant with respect to the claimed braided suture.

When the focus is shifted to the more relevant aspect of the Kaplan disclosure, specifically the sheath yarn component, the Examiner has correctly pointed out that the sheath yarn component may be "fabricated from individual filaments having more than two different chemical compositions, one or more of which optionally being non-absorbable". (Column 9, lines 25-28). However, Kaplan neither teaches nor suggests how his sheath yarn component is to be fabricated from these dissimilar individual filaments, nor is there any guidance to one skilled in the art as to how such dissimilar individual filaments are to be braided. Accordingly, just as was the case with the deficient Doddi reference, one skilled in the art could only be lead to randomly braid the dissimilar individual filaments into a braid construction.

The teaching of Kaplan once again lacks the essence of the claimed invention, which is: bundled filaments of a first fiber-forming material form a first set of a multifilament yarns, and at least one of these multifilament yarns is intertwined with a multifilament yarn composed of bundled filaments of a second fiber-forming material. To put it bluntly, Kaplan teaches randomized braiding, and the claimed suture sets forth a structured braid. This difference is not trivial, as pointed out with reference to the discussion of Applicant's specification, and particularly Examples 1 and 2.

It should also be pointed out here that even if Doddi and Kaplan were combined, their combined teachings would still fail to meet the limitations of the claimed braided suture. This is so because neither reference, taken singularly or in combination, discloses a structured braid set forth in the claims, but merely sets forth randomized braiding of individual filaments.

For all of the reasons given above, especially taken in light of the detailed discussion of the claimed braided suture and its surprising advantages, the rejection of claims 22 and 24 under 35 USC §103 as being unpatentable over Kaplan taken with Doddi is improper. Accordingly, it is respectfully requested that this rejection be withdrawn.


3. Applicants acknowledge with gratitude the withdrawal of the rejection of claims 21-24 under 35 USC §103 as being unpatentable over Burgess, expressed in the previous Office Action dated July 8, 1992. (Paper No. 3). It is presumed that Applicants' response to this rejection in their Amendment dated August 6, 1992, spelling out the distinctions between Burgess and the claimed

invention, clearly convinced the Examiner that the claimed surgical suture is patentable over this art.

4. The prior art made of record and not relied upon by the Examiner is duly noted, and does not affect the patentability of Applicants' claimed invention.

5. Since all formal requirements appear to have been met, and the claimed invention is patentable over the art of record or any other art of which Applicants are aware, Applicants respectfully solicit a Notice of Allowance at the Examiner's earliest convenience.

Respectfully submitted,



Matthew S. Goodwin
Attorney for Applicant
Reg. No. 32,839

Johnson & Johnson
One Johnson & Johnson Plaza
New Brunswick, NJ 08933-7003
(908) 524-2794
December 2, 1992

Case Docket No.: ETH-782

In re application of Alastair W. Hunter et al.

Serial No. 838,111

Filed 21 DECEMBER 4, 1992

For PATENT & TRADEMARKS STERILIZED HETEROGENEOUS BRAIDS

THE COMMISSIONER OF PATENTS AND TRADEMARKS
Washington, D.C. 20231

RECEIVED

DEC 10 1992

GROUP 1500

Sir:

Transmitted herewith is an amendment in the above-identified application.

 No additional fee is enclosed because this application was filed prior to October 25, 1965 (effective date of Public Law 89-83). No additional fee is required. One stamped, self-addressed postcard for the PTO Mail Room date stamp. Petition For Extension of Time and charge to Deposit Account of Appropriate Fee.

The fee has been calculated as shown below.

CLAIMS AS AMENDED

(1)	(2)	(3)	(4)	(5)	(6)	(7)
	CLAIMS REMAINING AFTER AMENDMENT		HIGHEST NO. PREVIOUSLY PAID FOR	PRESENT EXTRA	RATE	ADDITIONAL FEE
TOTAL CLAIMS	* 24	minus	** 24	= 0	x \$22	= \$ 000.00
INDEP. CLAIMS	* 1	minus	*** 3	= 0	x \$74	= \$ 000.00
TOTAL ADDITIONAL FEE FOR THIS AMENDMENT				\$ 000.00		

• If the entry in Col.2 is less than the entry in Col.4, write "0" in Col.5
 • If the "Highest Number Previously Paid For" IN THIS SPACE is less than 20, write "20" in this space.
 ** If the "Highest Number Previously Paid For" IN THIS SPACE is less than 3, write "3" in this space.

 Charge \$ 000.00 to Deposit Account No. 10-750/ETH-782/MSG. Three copies of this sheet are enclosed. Please charge any additional fees in connection with the filing of this communication, or credit overpayment, to Deposit Account No. 10-750/ETH-782/MSG. Three copies of this sheet are enclosed. A check in the amount of \$ _____ is attached.

Matthew S. Goodwin
Attorney of Record
Reg. No. 32,019

Matthew S. Goodwin
Johnson & Johnson
One Johnson & Johnson Plaza
New Brunswick, New Jersey 08933-7003
(908) 524-2791
December 2, 1992

DePuy Mitek, Inc. v. Arthrex, Inc.
C.A. No. 04-12457 PBS
DMI000243

In re Application of Alastair W. Hunter et al.

Serial No. 838,511

Filed, 1992 February 19, 1992

For STERILIZED HETEROGENEOUS BRAIDS

THE COMMISSIONER OF PATENTS AND TRADEMARKS
Washington, D.C. 20231

DEC 10 1992

GROUP 1500

Sir:

Transmitted herewith is an amendment in the above-identified application.

 No additional fee is enclosed because this application was filed prior to October 25, 1965 (effective date of Public Law 89-83). No additional fee is required. One stamped, self-addressed postcard for the PTO Mail Room date stamp. Petition For Extension of Time and charge to Deposit Account of Appropriate Fee.

The fee has been calculated as shown below.

CLAIMS AS AMENDED

(1)	(2)	(3)	(4)	(5)	(6)	(7)
	CLAIMS REMAINING AFTER AMENDMENT		HIGHEST NO. PREVIOUSLY PAID FOR	PRESENT EXTRA	RATE	ADDITIONAL FEE
TOTAL CLAIMS	* 24	minus	** 24	= 0	x \$22	= \$ 000.00
INDEP. CLAIMS	* 1	minus	*** 3	= 0	x \$74	= \$ 000.00
				TOTAL ADDITIONAL FEE FOR THIS AMENDMENT		\$ 000.00

* If the entry in Col.2 is less than the entry in Col.4, write "0" in Col.5.
 ** If the "Highest Number Previously Paid For" IN THIS SPACE is less than 20, write "20" in this space.
 *** If the "Highest Number Previously Paid For" IN THIS SPACE is less than 3, write "3" in this space.

 Charge \$ 000.00 to Deposit Account No. 10-750/ETH-782/MSG. Three copies of this sheet are enclosed. Please charge any additional fees in connection with the filing of this communication, or credit overpayment, to Deposit Account No. 10-750/ETH-782/MSG. Three copies of this sheet are enclosed. A check in the amount of \$ _____ is attached.Attorney of Record
Reg. No. 32,019

Matthew S. Goodwin
Johnson & Johnson
One Johnson & Johnson Plaza
New Brunswick, New Jersey 08903-7003
(908) 524-2791
December 2, 1992

In re application of Alastair W. Hunter et al.

Serial No. 838,511

DEC 4 1992

Filed February 19, 1992

For STERILIZED HETEROGENEOUS BRAIDS

THE COMMISSIONER OF PATENTS AND TRADEMARKS
Washington, D.C. 20231

DEC 10 1992

GPO 10-1500

Sir:

Transmitted herewith is an amendment in the above-identified application.

 No additional fee is enclosed because this application was filed prior to October 25, 1965 (effective date of Public Law 89-83). No additional fee is required. One stamped, self-addressed postcard for the PTO Mail Room date stamp. Petition For Extension of Time and charge to Deposit Account of Appropriate Fee.

The fee has been calculated as shown below.

CLAIMS AS AMENDED

(1)	(2)	(3)	(4)	(5)	(6)	(7)
	CLAIMS REMAINING AFTER AMENDMENT		HIGHEST NO. PREVIOUSLY PAID FOR	PRESENT EXTRA	RATE	ADDITIONAL FEE
TOTAL CLAIMS	* 24	minus	** 24	= 0	x \$22	= \$ 000.00
INDEP. CLAIMS	* 1	minus	*** 3	= 0	x \$74	= \$ 000.00
TOTAL ADDITIONAL FEE FOR THIS AMENDMENT				\$ 000.00		

* If the entry in Col. 2 is less than the entry in Col. 4, write "0" in Col. 5.
 ** If the "Highest Number Previously Paid For" IN THIS SPACE is less than 20, write "20" in this space.
 *** If the "Highest Number Previously Paid For" IN THIS SPACE is less than 3, write "3" in this space.

 Charge \$ 000.00 to Deposit Account No. 10-750/ETH-782/MSG. Three copies of this sheet are enclosed. Please charge any additional fees in connection with the filing of this communication, or credit overpayment, to Deposit Account No. 10-750/ETH-782/MSG. Three copies of this sheet are enclosed. A check in the amount of \$ _____ is attached.Attorney of Record
Reg. No. 32,019

Matthew S. Goodwin
Johnson & Johnson
One Johnson & Johnson Plaza
New Brunswick, New Jersey 08933-7003
(908) 524-2791
December 2, 1992



**UNITED STATES DEPARTMENT OF COMMERCE
Patent and Trademark Office**

Address : COMMISSIONER OF PATENTS AND TRADEMARKS
Washington, D.C. 20231

SERIAL NUMBER	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.
07/838,511	02/19/92	HUNTER	A ETH-782
			EXAMINER RAIMUNI, C
ROBERT L. MINIER ONE JOHNSON & JOHNSON PLAZA NEW BRUNSWICK, NJ 08933-7003			15N1 ART UNIT 1504 PAPER NUMBER 7 DATE MAILED: 03/18/93

This is a communication from the examiner in charge of your application.
COMMISSIONER OF PATENTS AND TRADEMARKS

This application has been examined Responsive to communication filed on Dec. 2, 1992 This action is made final.

A shortened statutory period for response to this action is set to expire 3 month(s), days from the date of this letter. Failure to respond within the period for response will cause the application to become abandoned. 35 U.S.C. 133

Part 1 THE FOLLOWING ATTACHMENT(S) ARE PART OF THIS ACTION:

1. Notice of References Cited by Examiner, PTO-892.
2. Notice re Patent Drawing, PTO-948.
3. Notice of Art Cited by Applicant, PTO-1448.
4. Notice of Informal Patent Application, Form PTO-152.
5. Information on How to Effect Drawing Changes, PTO-1474.
6. _____

Part II SUMMARY OF ACTION

1. Claims 1 - 24 are pending in the application.

Of the above, claims 1 - 20 are withdrawn from consideration.

2. Claims _____ have been cancelled.

3. Claims _____ are allowed.

4. Claims 21 - 24 are rejected.

5. Claims _____ are objected to.

6. Claims _____ are subject to restriction or election requirement.

7. This application has been filed with informal drawings under 37 C.F.R. 1.85 which are acceptable for examination purposes.

8. Formal drawings are required in response to this Office action.

9. The corrected or substitute drawings have been received on _____. Under 37 C.F.R. 1.84 these drawings are acceptable. not acceptable (see explanation or Notice re Patent Drawing, PTO-848).

10. The proposed additional or substitute sheet(s) of drawings, filed on _____ has (have) been approved by the examiner. disapproved by the examiner (see explanation).

11. The proposed drawing correction, filed on _____, has been approved. disapproved (see explanation).

12. Acknowledgment is made of the claim for priority under U.S.C. 119. The certified copy has been received not been received been filed in parent application, serial no. _____; filed on _____.

13. Since this application appears to be in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under Ex parte Quayle, 1935 C.D. 11; 453 O.G. 213.

14. Other _____

EXAMINER'S ACTION

DePuy Mitek, Inc. v. Arthrex, Inc.
C.A. No.04-12457 PBS
DMI000246

Serial No. 838,511

-2-

Art Unit 1504

The following is a quotation of the appropriate paragraphs of 35 U.S.C. § 102 that form the basis for the rejections under this section made in this Office action:

A person shall be entitled to a patent unless --
(e) the invention was described in a patent granted on an application for patent by another filed in the United States before the invention thereof by the applicant for patent, or on an international application by another who has fulfilled the requirements of paragraphs (1), (2), and (4) of section 371(c) of this title before the invention thereof by the applicant for patent.

Claim 21 is rejected under 35 U.S.C. § 102(e) as being anticipated by Kaplan et al.

Kaplan et al. discloses a connective tissue prosthesis comprising a braided sheath yarn component and a core yarn component. The braided sheath comprises braided filaments or braided filament bundles (column 9, lines 4-12). A sheath component containing filaments of different chemical compositions is specifically disclosed (column 9, lines 12-16). Claim 21 is therefore anticipated by Kaplan et al.

The following is a quotation of 35 U.S.C. § 103 which forms the basis for all obviousness rejections set forth in this Office action:

A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negated by the manner in which the invention was made.

Subject matter developed by another person, which qualifies as

Serial No. 838,511

-3-

Art Unit 1504

prior art only under subsection (f) or (g) of section 102 of this title, shall not preclude patentability under this section where the subject matter and the claimed invention were, at the time the invention was made, owned by the same person or subject to an obligation of assignment to the same person.

Claims 21-24 are rejected under 35 U.S.C. § 103 as being unpatentable over Doddi et al. taken with Kaplan et al.

Doddi et al. disclose a surgical suture comprising filaments of two different polymers in a braided configuration (column 9, lines 47-56). Suitable biocompatible, non absorbable filaments include PET and PTFE (column 9, lines 51-53).

Kaplan et al. discloses a ligament prosthesis comprising a core component and a braided sheath component. The core component is "made up of one or more biocompatible, essentially non-bioabsorbable..." filaments (column 9, lines 1-3). The sheath yarn component may be fabricated from one or more non-bioabsorbable fibers (column 9, lines 25-28). It would have been obvious to form the sheath component of the device of Kaplan et al. from PTFE and PET. PTFE is known to impart improved knot run down properties to sutures (see Block U.S. Pat. No. 3,527,650). PET is noted for its low cost and high strength. The core yarn component must be non-bioabsorbable (column 4, lines 45-46). Since PET is non-bioabsorbable, biocompatible and has the desirable properties noted above, its use as the core component would have been obvious. Claims 21 and 22 are therefore unpatentable over Doddi et al. taken

Serial No. 838,511

-4-

Art Unit 1504

with Kaplan et al.

Kaplan et al. fail to disclose the prosthesis of their invention connected to a needle. Prostheses are, however, implanted in the body using a needle. Claims 23 and 24 are therefore unpatentable over Doddi et al. taken with Kaplan et al.

Applicant's arguments with respect to claims 21-24 have been considered but are deemed to be moot in view of the new grounds of rejection.

Any inquiry concerning this communication should be directed to Chris Raimund at telephone number (703) 308-2374.



C. Raimund:pdw
February 25, 1993



GEORGE F. LESMES
SUPERVISORY PATENT EXAMINER
GROUP 150



ETH-782

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: Alastair W. Hunter, et al.

Serial No.: 838,511

Art Unit: 1504

Filed : February 19, 1992

Examiner: C. Raimund

For : STERILIZED HETEROGENEOUS BRAIDS

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner of Patents and Trademarks, Washington, D.C. 20231 on

August 4, 1993

(Date of Deposit)

Hal Brent Woodrow
Name of applicant, assignee, or Registered Representative

Hal Brent Woodrow
(Signature)

August 3, 1993

(Date of Signature)

RECEIVED
SEP 1 1993

Hon. Commissioner of Patents
and Trademarks
Washington, D.C. 20231

INFORMATION DISCLOSURE STATEMENT

Dear Sir:

Submitted herewith on Form PTO-1449, is a listing of documents known to the Applicants and/or their attorney in compliance with the requirements of 37 C.F.R. §1.56. Copies of these documents are also being submitted.

These documents are being submitted after the first Office Action. Accordingly, the Patent and Trademark Office is authorized to charge Account No. 10-750/ETH-782/HBW the appropriate fee under 37 C.F.R. §1.17(p) for the citation of these documents. Three copies of this statement are included.

CS14107 09/08/93 07838511

10-0750 140 126 200.00CH

DePuy Mitek, Inc. v. Arthrex, Inc.

C.A. No. 04-12457 PBS

DMI000250

Consideration of the cited documents and making the same of record in the prosecution of the above-noted application are respectfully requested.

Respectfully submitted,

Hal B. Woodrow
Hal B. Woodrow
Reg. No. 32,501

JOHNSON & JOHNSON
One Johnson and Johnson Plaza
New Brunswick, NJ 08933-7003
(908) 524-2976

ETH-782

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: Alastair W. Hunter, et al.
Serial No.: 838,511 Art Unit: 1504
Filed : February 19, 1992 Examiner: C. Raimund
For : STERILIZED HETEROGENEOUS BRAIDS

I hereby certify that this correspondence is being deposited with the
United States Postal Service as first class mail in an envelope addressed
to: Commissioner of Patents and Trademarks, Washington, D.C. 20231 on

August 4, 1993
(Date of Deposit)

Hal Brent (Woodrow)
Name of applicant, assignee, or Registered Representative

Hal Brent (Woodrow)
(Signature)

August 3, 1993
(Date of Signature)

Hon. Commissioner of Patents
and Trademarks
Washington, D.C. 20231

INFORMATION DISCLOSURE STATEMENT

Dear Sir:

Submitted herewith on Form PTO-1449, is a listing of documents known to the Applicants and/or their attorney in compliance with the requirements of 37 C.F.R. §1.56. Copies of these documents are also being submitted.

These documents are being submitted after the first Office Action. Accordingly, the Patent and Trademark Office is authorized to charge Account No. 10-750/ETH-782/HBW the appropriate fee under 37 C.F.R. §1.17(p) for the citation of these documents. Three copies of this statement are included.

Consideration of the cited documents and making the same of record in the prosecution of the above-noted application are respectfully requested.

Respectfully submitted,

Hal B. Woodrow
Hal B. Woodrow
Reg. No. 32,501

JOHNSON & JOHNSON
One Johnson and Johnson Plaza
New Brunswick, NJ 08933-7003
(908) 524-2976

Sheet 1 of 1

Form M-0-1449	Docket No. ETH-782	Serial No. 838,511
INFORMATION DISCLOSURE CITATION IN AN APPLICATION	Applicant Alastair W. Hunter, et al.	
	Filing Date Feb. 19, 1992	Group Aa Unit 1504

U. S. PATENT DOCUMENTS


FOREIGN PATENT DOCUMENTS

Exam'r Init.	Document No.	Date	Country	Class	Sub Class	Translate Yes	Translate No
CWR	GB 2 082 213	8/16/80	Great Britain			✓	

OTHER REFERENCES (include author, title, date, pertinent pages, etc.)

DePuy Mitek, Inc. v. Arthrex, Inc.
C.A. No.04-12457 PBS
DMI000254

 <small>Examiner</small>	<small>Date Considered</small> NOVEMBER 8, 1993
--	---



DOCKET NO. ETH-782

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: Alastair W. Hunter, et al.

Serial No.: 838,511 Art Unit: 1504

Filed : February 19, 1992 Examiner: C. Raimund

For : STERILIZED HETEROGENEOUS BRAIDS

Hon. Commissioner of Patents
and Trademarks
Washington, D.C. 20231


ASSOCIATE POWER OF ATTORNEY

Sir:

In the matter of the above-identified application, I hereby appoint Hal Woodrow (Reg. No. 32,501), whose postal address is One Johnson & Johnson Plaza, New Brunswick, New Jersey 08933-7003, my associate attorney to prosecute said application, to make alterations and amendments therein, to file continuing applications claiming the benefit of said application, to receive the patent and to transact all business in the Patent Office connected with said application.

I request all communications with respect to said application be addressed to Audley A. Ciamporcero, Jr., One Johnson & Johnson Plaza, New Brunswick, New Jersey 08933-7003. All telephone calls should be directed to Hal Woodrow at (908) 524-2976.

Signed at New Brunswick, in the County of Middlesex and State of New Jersey, this 3rd day of August, 1993.



Attorney for Applicant(s)
Jason Lipow Reg. No. 25509

One Johnson & Johnson Plaza
New Brunswick, NJ 08933-7003
(908) 524-2976
DATED: August 3, 1993

42 MAIL
AUG
9
1993

DCKET NO. ETH-782 (P154)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: Alastair W. Hunter, et al.

Serial No.: 838,511 Art Unit: 1504

Filed : February 19, 1992 Examiner: C. Raimund

For : STERILIZED HETEROGENEOUS BRAIDS

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner of Patents and Trademarks, Washington, D.C. 20231 on

August 4, 1993
(Date of Deposit)

Hal B. Woodrow
Name of applicant, assignee, or Registered Representative

Hal B. Woodrow
(Signature)

August 3, 1993
(Date of Signature)

SEP 1 1993

Hon. Commissioner of Patents
and Trademarks
Washington, D.C. 20231

PETITION FOR EXTENSION OF TIME
AND AUTHORIZATION TO CHARGE
DEPOSIT ACCOUNT THEREFOR

Dear Sir:

Applicant(s) petition(s) the Commissioner of Patents and Trademarks to extend the time for response to the Office Action dated March 18, 1993 for two (2) month(s) from June 18, 1993 to August 18, 1993. An Amendment responding to the aforesaid Office Action is being filed concurrently herewith.

Please charge Deposit Account No. 10-750/ETH-782/HBW in the name of Johnson & Johnson for the cost of filing this Petition. Three copies of this Petition are enclosed.

P 30003 08/30/93 07838511

Respectfully submitted,
10-0750 030 116 360.00CHHal B. WoodrowHal B. Woodrow
Reg. No. 32051
Attorney for Applicant(s)

Johnson & Johnson
One Johnson & Johnson Plaza
New Brunswick, NJ 08933-7003
(908) 524-2976
DATE: August 4, 1993

DePuy Mitek, Inc. v. Arthrex, Inc.

C.A. No. 04-12457 PBS

DMI000256

JCKET NO. ETH-782

42 AUG
9 1993

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: Alastair W. Hunter, et al.

TRADE MARK No.: 838,511 Art Unit: 1504

Filed : February 19, 1992 Examiner: C. Raimund

For : STERILIZED HETEROGENEOUS BRAIDS

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner of Patents and Trademarks, Washington, D.C. 20231 on

August 4, 1993
(Date of Deposit)

Hal B. Woodrow
Name of applicant, assignee, or Registered Representative

Hal B. Woodrow
(Signature)

August 3, 1993
(Date of signature)

Hon. Commissioner of Patents
and Trademarks
Washington, D.C. 20231

10634
1993

PETITION FOR EXTENSION OF TIME
AND AUTHORIZATION TO CHARGE
DEPOSIT ACCOUNT THEREFOR

Dear Sir:

Applicant(s) petition(s) the Commissioner of Patents and Trademarks to extend the time for response to the Office Action dated March 18, 1993 for two (2) month(s) from June 18, 1993 to August 18, 1993. An Amendment responding to the aforesaid Office Action is being filed concurrently herewith.

Please charge Deposit Account No. 10-750/ETH-782/HBW in the name of Johnson & Johnson for the cost of filing this Petition. Three copies of this Petition are enclosed.

Respectfully submitted,

Hal B. Woodrow
Hal B. Woodrow
Reg. No. 32051
Attorney for Applicant(s)

Johnson & Johnson
One Johnson & Johnson Plaza
New Brunswick, NJ 08933-7003
(908) 524-2976
DATE: August 4, 1993

DePuy Mitek, Inc. v. Arthrex, Inc.

C.A. No. 04-12457 PBS

DMI000257



ETH-782

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: Alastair W. Hunter, et al.

Serial No.: 838,511 Art Unit: 1504

Filed : February 19, 1992 Examiner: C. Raimund

For : STERILIZED HETEROGENEOUS BRAIDS

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner of Patents and Trademarks, Washington, D.C. 20231 on

August 4, 1993

(Date of deposit)

Hal B. Woodrow

Hal B. Woodrow

(Signature)

August 3, 1993

(Date of signature)

Hon. Commissioner of Patents
and Trademarks
Washington, D.C. 20231

AMENDMENT

Dear Sir:

This amendment is responsive to the Office Action of March 18, 1993.

IN THE CLAIMS

SEP 1 1993

Please amend claim 2 as follows:

(Once Amended)

CM 1. A surgical suture [comprising] consisting essentially of a [the] heterogeneous braid [of claim 1] composed of a first and second set of continuous and discrete yarns in a sterilized, braided construction wherein at least one yarn from the first set is in direct intertwining contact with a yarn from the second set; and

1. a) each yarn from the first set is composed of a plurality of filaments of a first fiber-forming material selected from the group consisting of PTFE, FEP, PFA, PVDF, PETFE, PP and PE; and

1. b) each yarn from the second set is composed of a plurality of filaments of a second fiber-forming material selected from the group consisting of PET, nylon and aramid; and

1. c) optionally a core.

26

CLAIM 2

DePuy Mitek, Inc. v. Arthrex, Inc.
C.A. No. 04-12457 PBS
DMI000258

REMARKS

4. Please note that the attorney prosecuting this application for the assignee, Johnson & Johnson, is now Hal Brent Woodrow (Reg. No. 32,501). This change has been authorized by the Associated Power Attorney submitted herewith. No change in the address for correspondence is necessary.

Claim 21 has been amend to place this claim in proper form for allowance. Claim 21 as amended claims a heterogeneous braid composed of a first and second set of yarns. The first set of yarns are made of a fiber-forming material selected from the group consisting of PTFE, FEP, PFA, PVDF, PETFE, PP, and PE materials. The second set of yarns are made of a fiber-forming material selected from the group consisting PET, nylon and aramid materials. Support for there amendments may be found in the specification on page 4, lines 12-22 and page 8, lines 3-23. Accordingly, applicants request entry of this amendment and reconsideration of claim 21.

The rejection of claim 21 under 35 U.S.C. §102(e) as being anticipated by Kaplan et al. has been reviewed. However, applicants respectfully submit that claim 21 as amended is not anticipated by Kaplan. Kaplan, as stated by the Examiner, describes a connective tissue prosthesis comprising a braided sheath yarn component and a core yarn component. The sheath yarn being a biocompatible yarn that is bioabsorbable or semi-bioabsorbable (column 9 lines 10-12). In one embodiment the sheath yarn could also contain a non-bioabsorbable yarn of one or more chemical composition (column 9 line 25-27). Claim 21 as amended does not claim a sheath yarn composed of a bioabsorbable yarn. Accordingly, Kaplan et al. does not anticipate claim 21 under 35 U.S.C. § 102(e). Therefore, applicants request reconsideration and withdrawal of the rejection of claim 21 as being anticipated by Kaplan et al.

Applicants have also reviewed the rejection of claims 21-24 under 35 U.S.C. § 103 as being unpatentable over Doddi et al. taken with Kaplan et al. However, applicants respectfully submit that claims 21-24 are patentable over these documents.

Doddi et al. describes (column 9, lines 46-56) multifilament sutures composed of p-dioxanone and/or 1,4 dioxepan-2-one and alkyl substituted derivatives that may be woven, braided or knitted, either alone or in combination with nonabsorbable fibers. Although Doddi is a significant contribution to the art, Doddi does not describe heterogeneous braids formed from a first set of yarn composed of a plurality of filaments formed from materials selected

from the group consisting of PTFE, FEP, PFA PVDF, PETFE, PP and PE; and a second set of yarn composed from a plurality of filaments formed from materials selected from the group consisting of PET, nylon and aramid. Accordingly, Doddi alone would not render the present invention obvious.

Kaplan et al. as discussed previously describes a prosthesis comprising a core component and a braided sheath component. The sheath component which is designed to "erode over time" (column 9, line 52) to leave only the nonabsorbable core component. The sheath, however, may optionally have, in addition to the bioabsorbable sheath yarn, one or more non-bioabsorbable filaments. Applicants, therefore, respectfully submit that Kaplan does not suggest or disclose combining a first set of nonabsorbable yarns (i.e. PTFE) and a second set of nonabsorbable yarn (i.e. PET). In fact, Kaplan teaches away from this combination.

In column 2, Kaplan describe one of the objects of their invention as being "a prosthesis being formed of a composite yarn wherein an elastic core yarn is wrapped with a relatively inelastic, bioabsorbable or semi-absorbable sheath yarn so as to exhibit the stress-strain properties of natural tissue" (column 2, lines 36-41). In column 4, Kaplan describes fluorinated hydrocarbons, polypropylene and polyethylene as elastic core polymers as opposed to the inelastic sheath polymers desired in the sheath. Thus, Kaplan appears to suggest that the sheath yarns listed by the applicant in claim 21 should not be used as in sheaths. Applicants respectfully submit that in view of Kaplan teaching away from the present invention that the combination of Kaplan with Doddi does not render the present invention obvious. Accordingly, Applicants request reconsideration and withdrawal of the rejection of claims 21-24.

The citation of Block (U.S. Patent No. 3,527,650) has also been considered, but is respectfully submitted to be non-analogous art. Block describes the use of PTFE particles on the external surface of a PET suture as a lubricant. Block, however, does not suggest or disclose PTFE fiber as having a lubricating effect. Therefore, Block's use of PTFE particles does not suggest or disclose the use of PTFE fibers in braids.

Applicants also wish to alert the Examiner to the applicants' intent to change the inventorship because of the reduced scope of the claims. Dennis D. Jamiołkowski will no longer appear as an inventor if the present claims are allowed. Papers to effectuate this changed inventorship will be submitted when one or more of the present claims are indicated to be allowable.

Respectfully requested,

Hal Brent Woodrow
Hal B. Woodrow
Reg. No. 32,501

Johnson & Johnson
One Johnson & Johnson Plaza
New Brunswick, NJ 08933-7003
(908) 524-2976
Date: August 31 1995



ETH-782

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: Alastair W. Hunter, et al.

Serial No.: 838,511 Art Unit: 1504

Filed : February 19, 1992 Examiner: C. Raimund

For : STERILIZED HETEROGENEOUS BRAIDS

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner of Patents and Trademarks, Washington, D.C. 20231 on

RECEIVED GROUP 150

NOV 10 1993

November 9, 1993

(Date of Deposit)

Hal Brent Woodrow

Name of applicant, assignee, or Registered Representative:

Hal Brent Woodrow

(Signature)

November 9, 1993

(Date of Signature)

Hon. Commissioner of Patents
and Trademarks
Washington, D.C. 20231

11-24-93
7560

Raimund

SUPPLEMENTAL AMENDMENT

Dear Sir:

This Supplemental Amendment is an amendment to the Amendment submitted on August 4, 1993.

REMARKS

Applicants have noticed that the Amendment of August 4, 1993 under the heading "In The Claims" states, "Please amend claim 2 as follows:", however, the claim designated as being amended is claim

Noted - corrected by Examiner -

M. Jones (SPE)

12-30-93

USSN 838,511

21. Applicants respectfully request this sentence be changed to read "Please amend claim 21 as follows:".

Hal Brent Woodrow
Hal Brent Woodrow
Reg. No. 32,501
Attorney for Applicant(s)

Johnson & Johnson
One Johnson & Johnson Plaza
New Brunswick, NJ 08933-7003
(908) 524-2976
November 9, 1993



UNITED STATES DEPARTMENT OF COMMERCE
Patent and Trademark Office
Address: COMMISSIONER OF PATENTS AND TRADEMARKS
Washington, D.C. 20231

SERIAL NUMBER	FILING DATE	HUNTER, FIRST NAMED APPLICANT	ATTORNEY DOCKET NO.
107039-514	02/27/92		

1EN1/11.0

EXAMINER

ROBERT L. MINIER
ONE JOHNSON & JOHNSON PLAZA
NEW BRUNSWICK, NJ 08830 7003

ATTORNEY	PAPER NUMBER
----------	--------------

11102403

DATE MAILED:

NOTICE OF ALLOWABILITY

PART I

- This communication is responsive to the Amendment filed August 9, 1993
- All the claims being allowable, PROSECUTION ON THE MERITS IS (OR REMAINS) CLOSED in this application. If not included herewith (or previously mailed), a Notice Of Allowance And Issue Fee Due or other appropriate communication will be sent in due course.
- The allowed claims are 21, 23, 24, 7, 8, 10-12, 14, 18-20
- The drawings filed on _____ are acceptable.
- Acknowledgment is made of the claim for priority under 35 U.S.C. 119. The certified copy has [...] been received. [...] not been received. [...] been filed in parent application Serial No. _____, filed on _____.
- Note the attached Examiner's Amendment.
- Note the attached Examiner Interview Summary Record, PTOL-413.
- Note the attached Examiner's Statement of Reasons for Allowance.
- Note the attached NOTICE OF REFERENCES CITED, PTO-892.
- Note the attached INFORMATION DISCLOSURE CITATION, PTO-1449.

PART II

A SHORTENED STATUTORY PERIOD FOR RESPONSE to comply with the requirements noted below is set to EXPIRE THREE MONTHS FROM THE "DATE MAILED" indicated on this form. Failure to timely comply will result in the ABANDONMENT of this application. Extensions of time may be obtained under the provisions of 37 CFR 1.136(a).

- Note the attached EXAMINER'S AMENDMENT or NOTICE OF INFORMAL APPLICATION, PTO-152, which discloses that the oath or declaration is deficient. A SUBSTITUTE OATH OR DECLARATION IS REQUIRED.
- APPLICANT MUST MAKE THE DRAWING CHANGES INDICATED BELOW IN THE MANNER SET FORTH ON THE REVERSE SIDE OF THIS PAPER.
 - Drawing Informalities are indicated on the NOTICE RE PATENT DRAWINGS, PTO-948, attached hereto or to Paper No. _____, CORRECTION IS REQUIRED.
 - The proposed drawing correction filed on _____ has been approved by the examiner. CORRECTION IS REQUIRED.
 - Approved drawing corrections are described by the examiner in the attached EXAMINER'S AMENDMENT. CORRECTION IS REQUIRED.
 - Formal drawings are now REQUIRED.

Any response to this letter should include in the upper right hand corner, the following information from the NOTICE OF ALLOWANCE AND ISSUE FEE DUE: ISSUE BATCH NUMBER, DATE OF THE NOTICE OF ALLOWANCE, AND SERIAL NUMBER.

Attachments:

- Examiner's Amendment
- Examiner Interview Summary Record, PTOL-413
- Reasons for Allowance
- Notice of References Cited, PTO-892
- Information Disclosure Citation, PTO-1449

- Notice of Informal Application, PTO-152
- Notice re Patent Drawings, PTO-948
- Listing of Bonded Draftsmen
- Other

DePuy Mitek, Inc. v. Arthrex, Inc.
C.A. No. 04-12457 PBS
DMI000264

Serial Number: 07/838,511

-2-

Art Unit: 1504

Part III EXAMINER'S AMENDMENT

An Examiner's Amendment to the record appears below. Should the changes and/or additions be unacceptable to applicant, an amendment may be filed as provided by 37 C.F.R. § 1.312. To ensure consideration of such an amendment, it **MUST** be submitted no later than the payment of the Issue Fee.

Authorization for this Examiner's Amendment was given in a telephone interview with Hal B. Woodrow on November 15, 1993.

Permission was given to amend the claims as follows:

Cancel claims 1, 6, 9, 13, 15, 16, 17 and 22.

In claims 7, 8, 10, 11, 12, 14, 18, 19 and 20, line 1, change "heterogeneous braid" to "surgical suture".

In claim 7, line 1, change "6" to "21".

In claim 10, line 1, change "9" to "8".

In claim 14, line 1, change "13" to "12".

In claim 18, line 1, change "17" to "14".

In claim 20, line 1, change "1" to "21".

In claim 24, line 1, change "22" to "14".

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Chris Raimund whose telephone number is (703) 308-2374.


Chris Raimund/cwr
November 15, 1993


GEORGE F. LESMES
SUPERVISORY PATENT EXAMINER
GROUP 150



UNITED STATES DEPARTMENT OF COMMERCE
Patent and Trademark Office

Address: Box ISSUE FEE
COMMISSIONER OF PATENTS AND TRADEMARKS
Washington, D.C. 20231

ROBERT L. MINTEN
ONE JEFFERSON & JOHNSON PLAZA
NEW BRUNSWICK, NJ 08903-7000

NOTICE OF ALLOWANCE
AND ISSUE FEE DUE

Note attached communication from the Examiner
 This notice is issued in view of applicant's communication filed _____

SERIES CODE/SERIAL NO.	FILING DATE	TOTAL CLAIMS	EXAMINER AND GROUP ART UNIT	DATE MAILED
574008-511	01/19/92	012	REG MINTEN, R.	1001 01/16/92
First Named Applicant	ROBERT L. MINTEN		ALASTAIR, K.	

TITLE OF
INVENTION: IDENTIFIED MICROSTRUCTURE BRAKE

ATTY'S DOCKET NO.	CLASS-SUBCLASS	BATCH NO.	APPLN. TYPE	SMALL ENTITY	FEES DUE	DATE DUE
3-574008-511	604-231,000	847	UTILITY	NO	\$117.00	01/16/92

THE FEE DUE IS THE AMOUNT IN EFFECT AT THIS TIME. IF THE AMOUNT OF THE ISSUE FEE INCREASES PRIOR TO PAYMENT, APPLICANT WILL BE NOTIFIED OF THE BALANCE OF ISSUE FEE DUE.

THE APPLICATION IDENTIFIED ABOVE HAS BEEN EXAMINED AND IS ALLOWED FOR ISSUANCE AS A PATENT.

PROSECUTION ON THE MERITS IS CLOSED.

THE ISSUE FEE MUST BE PAID WITHIN THREE MONTHS FROM THE MAILING DATE OF THIS NOTICE OR THIS APPLICATION SHALL BE REGARDED AS ABANDONED. THIS STATUTORY PERIOD CANNOT BE EXTENDED.

HOW TO RESPOND TO THIS NOTICE:

I. Review the SMALL ENTITY Status shown above.
If the SMALL ENTITY is shown as YES, verify your current SMALL ENTITY status:

A. If the status is changed, pay twice the amount of the FEE DUE shown above and notify the Patent and Trademark Office of the change in status, or
B. If the Status is the same, pay the FEE DUE shown above.


II. Part B of this notice should be completed and returned to the Patent and Trademark Office (PTO) with your ISSUE FEE. Even if the ISSUE FEE has already been paid by charge to deposit account, Part B should be completed and returned. If you are charging the ISSUE FEE to your deposit account, Part C of this notice should also be completed and returned.



III. All communications regarding this application must give series code (or filing date) and serial number. Please direct all communications prior to issuance to Box ISSUE FEE unless advised to contrary.

IMPORTANT REMINDER: Patents issuing on applications filed on or after Dec. 12, 1980 may require payment of maintenance fees. It is patentee's responsibility to ensure timely payment of maintenance fees when due.

PART B—ISSUE FEE TRANSMITTAL

MAILING INSTRUCTIONS: This form should be used for transmitting the ISSUE FEE. Blocks 2 through 6 should be completed where appropriate. All further correspondence including the Issue Fee Receipt, the Patent, advances orders and notification of maintenance fees will be mailed to address entered in Block 1, unless you direct otherwise, by: (a) specifying a new correspondence address in Block below, or (b) providing the PTO with a separate "FEE ADDRESS" for maintenance fee notifications with the payment of Issue Fee or thereafter. See reverse for Certificate of Mailing.

1 CORRESPONDENCE ADDRESS		2 INVENTOR(S) ADDRESS CHANGE (Complete only if there is a change)	
 DEPUTY, MITEK 1200 SOMERVILLE JOHNSON PLAZA 4000 PARK AVE MAILING ADDRESS 4000 PARK AVE		INVENTOR'S NAME Street Address City, State and ZIP Code CO-INVENTOR'S NAME Street Address City, State and ZIP Code	
<input type="checkbox"/> Check if additional changes are on reverse side			

SERIES CODE/SERIAL NO.	FILING DATE	TOTAL CLAIMS	EXAMINER/NAME GROUP ART UNIT	CON	DATE MAILED
30432 02/22/94 01 641 MUNI 241 2/18/94					
First Named Applicant					Hal Brent Woodrow
TITLE OF INVENTION					
ATTY'S DOCKET NO.	CLASS-SUBCLASS	BATCH NO.	APPN. TYPE	SMALL ENTITY	FEES DUE
ETH-281	606-231.000	567	UTILITY	00	411.00 00 0.00 00

3. Correspondence address change (Complete only if there is a change)	4. For printing on the patent front page, list the names of not more than 3 registered patent attorneys or agents OR alternatively, the name of a firm having as a member a registered attorney or agent. If no names listed, no name will be printed.
P. 30432 02/22/94 07838511 P. 30432 02/22/94 07838511	10-0 10-0 Hal Brent Woodrow 170.00 CH 30.00 CA

DO NOT USE THIS SPACE

5. ASSIGNMENT DATA TO BE PRINTED ON THE PATENT (print or type)	6a. The following fees are enclosed:
(1) NAME OF ASSIGNEE	<input type="checkbox"/> Issue Fee <input type="checkbox"/> Advanced Order - # of Copies _____
DePuy Mitek, Inc. Recorded- 2/19/92 Reel-6023	<input type="checkbox"/> Any Deficiencies in Enclosed Fees _____
(2) ADDRESS (CITY & STATE OR COUNTY)	6b. The following fees should be charged to: 10-0750 (Minimum of 10)
SOMERVILLE, N.J.	<input type="checkbox"/> DEPOSIT ACCOUNT NUMBER 10-0750
(3) STATE OF INCORPORATION, IF ASSIGNEE IS A CORPORATION	<input type="checkbox"/> Advanced Order - # of Copies _____
Ohio	<input type="checkbox"/> Any Deficiencies in Enclosed Fees _____
A <input type="checkbox"/> This application is NOT assigned. X Assignment is being previously submitted to the Patent and Trademark Office. <input type="checkbox"/> Assignment is being submitted under separate cover. Assignments should be directed to Box ASSIGNMENTS.	
PLEASE NOTE: Unless an assignee is identified in Block 5, no assignee data will appear on the patent. Inclusion of assignee data is only appropriate when an assignment has been previously submitted to the PTO or is being submitted under separate cover. Completion of this form is NOT a substitute for filing an assignment.	
The COMMISSIONER OF PATENTS AND TRADEMARKS is requested to apply the Issue Fee to the application identified above. (Signature of party in interest of record) 32,501 Hal Brent W Woodrow (Date) 2/16/94	
NOTE: The Issue Fee will not be accepted from anyone other than the applicant, a registered attorney or agent, or the assignee or other party in interest as shown by the records of the Patent and Trademark Office.	

TRANSMIT THIS FORM WITH FEE-CERTIFICATE OF MAILING ON REVERSE

PTOL-858 (REV.7-92)(OMB Clearance is pending)

DePuy Mitek, Inc. v. Arthrex, Inc.

C.A. No. 04-12457 PBS

DMI000267

Certificate of Mailing

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to:

Box ISSUE FEE
Commissioner of Patents and Trademarks
Washington, D.C. 20231

on February 16, 1994
(Date)

Hal Brent Woodrow
(Signature)

Hal Brent Woodrow
(Typed or Printed Name)

February 16, 1994
(Date)

Note: If this certificate of mailing is used, it can only be used to transmit the Issue Fee. This certificate cannot be used for any other accompanying papers. Each additional paper, such as an assignment or formal drawing, must have its own certificate of mailing.

This form is estimated to take 20 minutes to Complete. Time will vary depending upon the needs of the individual applicant. Any comments on the amount of time you require to complete this form should be sent to the Office of Management and Organization, Patent and Trademark Office, Washington, D.C. 20231 and to the Office of Information and Regulatory Affairs, Office of Management and Budget, Washington, D.C. 20503.

PART B—ISSUE FEE TRANSMITTAL

MAILING INSTRUCTIONS: This form should be used for transmitting the ISSUE FEE. Blocks 2 through 6 should be completed where appropriate. All further correspondence including the Issue Fee Receipt, the Patent, advances orders and notification of maintenance fees will be mailed to addressee entered in Block 1 unless you direct otherwise, by: (a) specifying a new correspondence address in Block below; or (b) providing the PTO with a separate "FEE ADDRESS" for maintenance fee notifications with the payment of Issue Fee or thereafter. See reverse for Certificate of Mailing.

1. CORRESPONDENCE ADDRESS		2. INVENTOR(S) ADDRESS CHANGE (Complete only if there is a change)					
<p style="text-align: center;">MAIL ROOM</p> <p style="text-align: center;">68 FEB 18 1994</p> <p style="text-align: center;">TRADEMARKS</p> <p>ROBERT L. WOODROW ONE MONROE CENTER PLAZA NEW BRUNSWICK, NJ 08852-2100</p>		<p>INVENTOR'S NAME Street Address City, State and ZIP Code</p> <p>CO-INVENTOR'S NAME Street Address City, State and ZIP Code</p> <p><input type="checkbox"/> Check if additional changes are on reverse side</p>					
<p style="text-align: center;">138-1006 COMPOSITION OF RADIOPHARMACEUTICALS 2217-100</p>							
SERIES CODE/SERIAL NO.		FILING DATE	TOTAL CLAIMS				
107-1006-100		11/10/93	1				
First Name, Applicant		EXAMINER AND GROUP ART UNIT					
JULIA L. WOODROW		11/10/93					
TITLE OF INVENTION		DATE MAILED					
REFLECTIVE POLY(URIDYLIC ACID)		11/10/93					
ATTY'S DOCKET NO.		CLASS-SUBCLASS	BATCH NO.	APPLN. TYPE	SMALL ENTITY	FEES DUE	DATE DUE
ETH-100		406-200	000	UTILITY NO	11170.00	02/18/94	
<p>Note: If this application is filed to facilitate a search, it can only be used to insure timely issue. This application cannot be used for such other purposes.</p> <p>Fee Basis: Each application shall be charged as an assignment of patent or trademark unless otherwise specified in the application.</p>							
Correspondence address change (Complete only if there is a change)				<p>4. For printing on the patent front page, list the names of not more than 3 registered patent attorneys or agents OR alternatively, the name of a firm having as a member a registered attorney or agent. If no name is listed, no name will be printed.</p> <p>1 Hal Brent Woodrow 2 _____ 3 _____</p>			

5. ASSIGNMENT DATA TO BE PRINTED ON THE PATENT (print or type)

(1) NAME OF ASSIGNEE **Ethicon, Inc.** Recorded **2/19/92 Reel-6023**

(2) ADDRESS, (CITY & STATE OR COUNTY) **Frame 941
Somerville, N.J.**

(3) STATE OF INCORPORATION, IF ASSIGNEE IS A CORPORATION **Ohio**

This application is NOT assigned.
 Assignment is being previously submitted to the Patent and Trademark Office.
 Assignment is being submitted under separate cover. Assignments should be directed to Box ASSIGNMENTS.

PLEASE NOTE: Unless an assignee is identified in Block 5, no assignee data will appear on the patent. Inclusion of assignee data is only appropriate when an assignment has been previously submitted to the PTO or is being submitted under separate cover. Completion of this form is NOT a substitute for filing an assignment.

6. The following fees are enclosed:
 Issue Fee Advanced Order - # of Copies _____ (Minimum of 10)
 The following letter should be changed to: _____

7. DEPOSIT ACCOUNT NUMBER **10-0750**

(ENCLOSED PART C)

Issue Fee Advanced Order - # of Copies **10**
 Any Deficiencies in Enclosed Fees _____ (Minimum of 10)

The COMMISSIONER OF PATENTS AND TRADEMARKS is requested to apply the Issue Fee to the application identified above.

(Signature of party in interest of record) **32,501 Had Bent W Becker** (Date) **2/16/94**

NOTE: If the Issue Fee will not be accepted from anyone other than the applicant, a registered attorney or agent, or the assignee or other party in interest as shown by the records of the Patent and Trademark Office.

TRANSMIT THIS FORM WITH FEE-CERTIFICATE OF MAILING ON REVERSE

DePuy Mitek, Inc. v. Arthrex, Inc.
C.A. No.04-12457 PBS
DMI000269

A. M. ART 303 3028-8 7149

~~www.~~ - Certificate of Mailing

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to:

Box 1 ISSUE FEE
Commissioner of Patents and Trademarks
Washington, D.C. 20231

(Punto)

Note: If this certificate of mailing is used, it can only be used to transmit the Issue Fee. This certificate cannot be used for any other accompanying papers. Each additional paper, such as an assignment or formal drawing, must have its own certificate of mailing.

DePuy Mitek, Inc. v. Arthrex, Inc.
C.A. No. 04-12457 PBS
DMI000270

This form is estimated to take 20 minutes to Complete. Time will vary

depending upon the needs of the individual applicant. Any additional term should be sent to the

The amount of time you require to complete this form (in hours)

Office of Management and Organization Page 5 of 5
Information and Regulation

Washington, D.C. 20503.

Office of Management and Budget, Washington, D.C. 20503 (202) 395-4000

NO. 10000001 has been filed on 01/01/2010

20000.00 DOLLARS APRIL THIRTEEN EIGHTY EIGHT

... 3 months or until the 21st day of December, 1961.

and no weapons like shotguns or rifles or anything like that.

10. *Leucosia* (Leucosia) *leucosia* (L.) *leucosia* (L.)

— 20 — ГЛАВА ВЪЛНОВЪДЪТ ВЪЛНОВЪДЪТ

THE WILL OF ERASERHUS MONTFORT

(OMB Clearance is pending)

REVERSE ETOL 458 (REV. 7-92)(OMB Clearance is pending)

RECORDED - INDEXED - SERIALIZED - FILED



ETH: 782

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Alastair W. Hunter, Dennis D. Jamiolkowski
 and Arthur Taylor, Jr.

Serial No. 07/838,511 Group No. 1504

Filed: February 19, 1992 Examiner: C. Raimund

For: STERILIZED HETEROGENOUS BRAIDS

CERTIFICATE OF MAILING (37 CFR 1.8(a))

RECEIVED

DEC 08 1993

I hereby certify that this paper (along with any paper referred to as being attached or enclosed) is being deposited with the United States Postal Service on the date shown below with sufficient postage as first class mail in an envelope addressed to the: Commissioner of Patents and Trademarks, Washington, D.C. 20231.

Hal Brent Woodrow
 Name of Person Mailing Paper

Date: November 22, 1993

Hal Brent Woodrow
 Signature of Person Mailing Paper

12-6-93

7560

Raimund

Commissioner of Patents and Trademarks
 Washington, D. C. 20231

AMENDMENT, PETITION AND FEE DELETING CORRECTLY NAMED
 ORIGINAL PERSON(S) WHO ARE NOT INVENTOR(S) OF INVENTION NOW
 BEING CLAIMED (37 CFR 1.48(b))

1. This amendment and petition under 37 CFR 1.48(b) is to delete the name(s) of the following person(s) originally named as inventor(s) of the invention now being claimed:

Dennis D. Jamiolkowski

2. Claims Now On File

The claims in this application are as follows:

originally filed claim(s) _____

originally filed claims _____ as amended on _____

claim(s) _____ filed on _____

claim(s) 21-24 filed on February 19, 1992 as amended on August 4, 1993 and amended by the Examiner's Amendment of

P 30079 November 02, 1993 10-0750 : 0 170-0009

USSN 07/838,511

claims 25-33 added by the Examiner's Amendment of November 15, 1993

3. DILIGENCE

This amendment and petition is being filed

diligently after discovery that any claim(s) for which the above-named inventor who is being deleted are now no longer the inventor of the subject matter being claimed.

4. STATUS OF INVENTORSHIP AFTER AMENDMENT

Attached is an explanation of the facts, including the ownership of all the claim(s) at the time the last claimed invention was made (Declaration of Inventorship and Common Ownership of Claims in Application).

5. FEE (37 CFR 1.17(h))

The fee required is paid as follow:

charge Account No. 10-750/HBW/ETH-782 for any fee deficiency

charge Account No. 10-750/HBW/ETH-782 the sum of \$130.00

Hal Brent Woodrow
Hal Brent Woodrow
Reg. No. 32,501

Johnson & Johnson
One Johnson & Johnson Plaza
New Brunswick, NJ 08933-7003
(908) 524-2976
November 22, 1993

PTO UTILITY GRANT

Paper Number 14

The
United
States
of
America



PTO-1584

The Commissioner of Patents
and Trademarks

Has received an application for a patent
for a new and useful invention. The title
and description of the invention are en-
closed. The requirements of law have
been complied with, and it has been de-
termined that a patent on the invention
shall be granted under the law.

Therefore, this

United States Patent

Grants to the person or persons having
title to this patent the right to exclude
others from making, using or selling the
invention throughout the United States
of America for the term of seventeen
years from the date of this patent, sub-
ject to the payment of maintenance fees
as provided by law.


Bruce Lehman

Commissioner of Patents and Trademarks

Sancho J. Morton

Attest

DePuy Mitek, Inc. v. Arthrex, Inc.
C.A. No. 04-12457 PBS
DMI000273



UNITED STATES DEPARTMENT OF COMMERCE

Patent and Trademark Office

Address: COMMISSIONER OF PATENTS AND TRADEMARKS
Washington, D.C. 20231

SERIAL NUMBER	FILING DATE	FIRST NAME AND LAST NAME	ATTORNEY OR AGENT
171311-511	02/19/92	HUNTER	15014
		15N1711522	EXAMINER
			ART. UNIT
			15014
			PAPER NUMBER
			DATE MAILED
			05/27/94

A. The petition filed _____ under 37 CFR 1.312(b) is granted.
The paper has been forwarded to the examiner for consideration on the merits.

B. The amendment filed 2/16/94 under 37 CFR 1.312 has been considered, and has been:

1. entered
2. entered as directed to matters of form not affecting the scope of the invention (0.3311).
3. disapproved. A report appears below.
4. entered in part. A report appears below.

Report:



DePuy Mitek, Inc.
SUPERVISOR OF EXAMINERS
C.R.O. P150

PLEASE FURNISH YOUR ZIP CODE IN ALL CORRESPONDENCE

DePuy Mitek, Inc. v. Arthrex, Inc.

C.A. No. 04-12457 PBS

DMI000274




□ = 100% NON-ABSORBABLE
□ = 75% NON-ABSORBABLE - 25% FGA
□ = 50% NON-ABSORBABLE - 50% PGA
□ = 25% NON-ABSORBABLE - 75% PGA

27-28-29

INVENTORS:
EDWARD EMIL SCHMITT
ROCCO ALBERT POLISTINA
BY
Samuel Bracha, Esq.
ATTORNEY

REINFORCED FABRIC



~~SEARCHED~~ - ~~E~~


INVENTORS
EDWARD EMIL SCHMITT
ROCCO ALBERT POLISTINA
BY


Samuel Brandstetter
ATTORNEY

DePuy Mitek, Inc. v. Arthrex, Inc.

C.A. No. 04-12457-PBS

DMI000276





7-2-27-10

INVENTORS.
EDWARD EMIL SCHMITT
ROCCO ALBERT POLISTINA
BY

Samuel Brandis, Esq.
ATTORNEY

FIGURE 10 shows a portion of a woven tube of cast 10
which is a solid polyglycolic acid.

FIGURE 11 shows a portion of a woven tube of cast 11
which is a solid polyglycolic acid. The tube is formed by
twisting together 15 strands of 1/16" diameter, each strand
being 1/16" in diameter and 15" long. The tube is 15" long
and has a 15/16" outside diameter and a 15/16" inside diameter.
The tube is woven from 15 strands of 1/16" diameter, each strand
being 1/16" in diameter and 15" long. The tube is 15" long
and has a 15/16" outside diameter and a 15/16" inside diameter.

FIGURE 12 shows a portion of a woven tube of cast 12
which is a solid polyglycolic acid. The tube is formed by
twisting together 15 strands of 1/16" diameter, each strand
being 1/16" in diameter and 15" long. The tube is 15" long
and has a 15/16" outside diameter and a 15/16" inside diameter.

FIGURE 13 shows a portion of a woven tube of cast 13
which is a solid polyglycolic acid.

FIGURE 14 shows a portion of a woven tube of cast 14
which is a solid polyglycolic acid.

FIGURE 15 shows a portion of a woven tube of cast 15
which is a solid polyglycolic acid.

FIGURE 16 shows a portion of a heart valve, produced
in heart tissue using a fabric in part composed of poly-
glycolic acid to aid in holding the valve in place.

FIGURE 17 shows a broken bone, the ends of which
are held together by a solid bar of polyglycolic acid
held to the bone by polyglycolic acid screws.

FIGURE 18 shows a broken bone, the ends of which
are held in position by an internal fixation pin of poly-
glycolic acid.

PGA for the construction of the prostheses shown in
the drawings can be produced as set forth in the following
example, in which parts are by weight, unless otherwise
clearly indicated:

EXAMPLE 1

100 parts of recrystallized glycolide (melting point
85.0 to 85.5° C.) are intimately mixed with 0.02 part of
methoxyacetic acid, 0.03 part of phenoldisulfide (Sanc-
o-Nox), and 0.01 part antimony trisulfide. Separate glass
tubes are each charged with approximately 20 grams of
the mixture, deoxygenated by repeated evacuation and
argon purging, then sealed under vacuum and heated to
185 to 190° C. for 48 hours. On cooling a white opaque
tough PGA is produced in a 97.5% yield with a melt
viscosity at 245° C. of 5,000 poises. The polymer is re-
heated and spun into filaments at a temperature of about
230° C. at a speed of about 150 feet per minute. The fila-
ments produced are cooled, then drawn at about 52° C.
When drawn five times the original length a strong
tough filament is produced. The dry filaments are in condition for use.

EXAMPLE 2

The polymer of the preceding example is formed into
a plurality of smaller filaments, seven or eight, which are
twisted into a polyfilamentary strand, which is then
twisted and woven following the techniques of FIGURE 10.

Because it is a synthetic polymer the relative proportions
are more variable than in starting with natural or
existing materials.

The polymer of the preceding example is formed into
a plurality of smaller filaments, seven or eight, which are
twisted into a polyfilamentary strand, which is then
twisted and woven following the techniques of FIGURE 10.
The polymer of the preceding example is formed into
a plurality of smaller filaments, seven or eight, which are
twisted into a polyfilamentary strand, which is then
twisted and woven following the techniques of FIGURE 10.
The polymer of the preceding example is formed into
a plurality of smaller filaments, seven or eight, which are
twisted into a polyfilamentary strand, which is then
twisted and woven following the techniques of FIGURE 10.

The polymer of the preceding example is formed into

the techniques of FIGURE 10. The polymer of the preceding
example is formed into the techniques of FIGURE 10.

The polymer of the preceding example is formed into
the techniques of FIGURE 10. The polymer of the preceding
example is formed into the techniques of FIGURE 10.

The polymer of the preceding example is formed into
the techniques of FIGURE 10. The polymer of the preceding
example is formed into the techniques of FIGURE 10.

The polymer of the preceding example is formed into
the techniques of FIGURE 10. The polymer of the preceding
example is formed into the techniques of FIGURE 10.

The polymer of the preceding example is formed into
the techniques of FIGURE 10. The polymer of the preceding
example is formed into the techniques of FIGURE 10.

The polymer of the preceding example is formed into
the techniques of FIGURE 10. The polymer of the preceding
example is formed into the techniques of FIGURE 10.

The polymer of the preceding example is formed into
the techniques of FIGURE 10. The polymer of the preceding
example is formed into the techniques of FIGURE 10.

The polymer of the preceding example is formed into
the techniques of FIGURE 10. The polymer of the preceding
example is formed into the techniques of FIGURE 10.

The polymer of the preceding example is formed into
the techniques of FIGURE 10. The polymer of the preceding
example is formed into the techniques of FIGURE 10.

The polymer of the preceding example is formed into
the techniques of FIGURE 10. The polymer of the preceding
example is formed into the techniques of FIGURE 10.

The polymer of the preceding example is formed into
the techniques of FIGURE 10. The polymer of the preceding
example is formed into the techniques of FIGURE 10.

The polymer of the preceding example is formed into
the techniques of FIGURE 10. The polymer of the preceding
example is formed into the techniques of FIGURE 10.

The polymer of the preceding example is formed into
the techniques of FIGURE 10. The polymer of the preceding
example is formed into the techniques of FIGURE 10.

The polymer of the preceding example is formed into
the techniques of FIGURE 10. The polymer of the preceding
example is formed into the techniques of FIGURE 10.

The polymer of the preceding example is formed into
the techniques of FIGURE 10. The polymer of the preceding
example is formed into the techniques of FIGURE 10.

The polymer of the preceding example is formed into
the techniques of FIGURE 10. The polymer of the preceding
example is formed into the techniques of FIGURE 10.

The polymer of the preceding example is formed into
the techniques of FIGURE 10. The polymer of the preceding
example is formed into the techniques of FIGURE 10.

The polymer of the preceding example is formed into
the techniques of FIGURE 10. The polymer of the preceding
example is formed into the techniques of FIGURE 10.

The polymer of the preceding example is formed into
the techniques of FIGURE 10. The polymer of the preceding
example is formed into the techniques of FIGURE 10.

The polymer of the preceding example is formed into
the techniques of FIGURE 10. The polymer of the preceding
example is formed into the techniques of FIGURE 10.

The polymer of the preceding example is formed into
the techniques of FIGURE 10. The polymer of the preceding
example is formed into the techniques of FIGURE 10.

The polymer of the preceding example is formed into
the techniques of FIGURE 10. The polymer of the preceding
example is formed into the techniques of FIGURE 10.

The polymer of the preceding example is formed into
the techniques of FIGURE 10. The polymer of the preceding
example is formed into the techniques of FIGURE 10.

The polymer of the preceding example is formed into
the techniques of FIGURE 10. The polymer of the preceding
example is formed into the techniques of FIGURE 10.

10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
66
67
68
69
70
71
72
73
74
75
76
77
78
79
80
81
82
83
84
85
86
87
88
89
90
91
92
93
94
95
96
97
98
99
100
101
102
103
104
105
106
107
108
109
110
111
112
113
114
115
116
117
118
119
120
121
122
123
124
125
126
127
128
129
130
131
132
133
134
135
136
137
138
139
140
141
142
143
144
145
146
147
148
149
150
151
152
153
154
155
156
157
158
159
160
161
162
163
164
165
166
167
168
169
170
171
172
173
174
175
176
177
178
179
180
181
182
183
184
185
186
187
188
189
190
191
192
193
194
195
196
197
198
199
200
201
202
203
204
205
206
207
208
209
210
211
212
213
214
215
216
217
218
219
220
221
222
223
224
225
226
227
228
229
230
231
232
233
234
235
236
237
238
239
240
241
242
243
244
245
246
247
248
249
250
251
252
253
254
255
256
257
258
259
260
261
262
263
264
265
266
267
268
269
270
271
272
273
274
275
276
277
278
279
280
281
282
283
284
285
286
287
288
289
290
291
292
293
294
295
296
297
298
299
300
301
302
303
304
305
306
307
308
309
310
311
312
313
314
315
316
317
318
319
320
321
322
323
324
325
326
327
328
329
330
331
332
333
334
335
336
337
338
339
340
341
342
343
344
345
346
347
348
349
350
351
352
353
354
355
356
357
358
359
360
361
362
363
364
365
366
367
368
369
370
371
372
373
374
375
376
377
378
379
380
381
382
383
384
385
386
387
388
389
390
391
392
393
394
395
396
397
398
399
400
401
402
403
404
405
406
407
408
409
410
411
412
413
414
415
416
417
418
419
420
421
422
423
424
425
426
427
428
429
430
431
432
433
434
435
436
437
438
439
440
441
442
443
444
445
446
447
448
449
450
451
452
453
454
455
456
457
458
459
460
461
462
463
464
465
466
467
468
469
470
471
472
473
474
475
476
477
478
479
480
481
482
483
484
485
486
487
488
489
490
491
492
493
494
495
496
497
498
499
500
501
502
503
504
505
506
507
508
509
510
511
512
513
514
515
516
517
518
519
520
521
522
523
524
525
526
527
528
529
530
531
532
533
534
535
536
537
538
539
540
541
542
543
544
545
546
547
548
549
550
551
552
553
554
555
556
557
558
559
559
560
561
562
563
564
565
566
567
568
569
569
570
571
572
573
574
575
576
577
578
579
579
580
581
582
583
584
585
586
587
588
589
589
590
591
592
593
594
595
596
597
598
599
599
600
601
602
603
604
605
606
607
608
609
609
610
611
612
613
614
615
616
617
618
619
619
620
621
622
623
624
625
626
627
628
629
629
630
631
632
633
634
635
636
637
638
639
639
640
641
642
643
644
645
646
647
648
649
649
650
651
652
653
654
655
656
657
658
659
659
660
661
662
663
664
665
666
667
668
669
669
670
671
672
673
674
675
676
677
678
679
679
680
681
682
683
684
685
686
687
688
689
689
690
691
692
693
694
695
696
697
698
699
699
700
701
702
703
704
705
706
707
708
709
709
710
711
712
713
714
715
716
717
718
719
719
720
721
722
723
724
725
726
727
728
729
729
730
731
732
733
734
735
736
737
738
739
739
740
741
742
743
744
745
746
747
748
749
749
750
751
752
753
754
755
756
757
758
759
759
760
761
762
763
764
765
766
767
768
769
769
770
771
772
773
774
775
776
777
778
779
779
780
781
782
783
784
785
786
787
788
789
789
790
791
792
793
794
795
796
797
798
799
799
800
801
802
803
804
805
806
807
808
809
809
810
811
812
813
814
815
816
817
818
819
819
820
821
822
823
824
825
826
827
828
829
829
830
831
832
833
834
835
836
837
838
839
839
840
841
842
843
844
845
846
847
848
849
849
850
851
852
853
854
855
856
857
858
859
859
860
861
862
863
864
865
866
867
868
869
869
870
871
872
873
874
875
876
877
878
879
879
880
881
882
883
884
885
886
887
888
889
889
890
891
892
893
894
895
896
897
898
899
899
900
901
902
903
904
905
906
907
908
909
909
910
911
912
913
914
915
916
917
918
919
919
920
921
922
923
924
925
926
927
928
929
929
930
931
932
933
934
935
936
937
938
939
939
940
941
942
943
944
945
946
947
948
949
949
950
951
952
953
954
955
956
957
958
959
959
960
961
962
963
964
965
966
967
968
969
969
970
971
972
973
974
975
976
977
978
979
979
980
981
982
983
984
985
986
987
988
989
989
990
991
992
993
994
995
996
997
998
999
1000
1001
1002
1003
1004
1005
1006
1007
1008
1009
1009
1010
1011
1012
1013
1014
1015
1016
1017
1018
1019
1019
1020
1021
1022
1023
1024
1025
1026
1027
1028
1029
1029
1030
1031
1032
1033
1034
1035
1036
1037
1038
1039
1039
1040
1041
1042
1043
1044
1045
1046
1047
1048
1049
1049
1050
1051
1052
1053
1054
1055
1056
1057
1058
1059
1059
1060
1061
1062
1063
1064
1065
1066
1067
1068
1069
1069
1070
1071
1072
1073
1074
1075
1076
1077
1078
1079
1079
1080
1081
1082
1083
1084
1085
1086
1087
1088
1089
1089
1090
1091
1092
1093
1094
1095
1096
1097
1098
1099
1100
1101
1102
1103
1104
1105
1106
1107
1108
1109
1109
1110
1111
1112
1113
1114
1115
1116
1117
1118
1119
1119
1120
1121
1122
1123
1124
1125
1126
1127
1128
1129
1129
1130
1131
1132
1133
1134
1135
1136
1137
1138
1139
1139
1140
1141
1142
1143
1144
1145
1146
1147
1148
1149
1149
1150
1151
1152
1153
1154
1155
1156
1157
1158
1159
1159
1160
1161
1162
1163
1164
1165
1166
1167
1168
1169
1169
1170
1171
1172
1173
1174
1175
1176
1177
1178
1179
1179
1180
1181
1182
1183
1184
1185
1186
1187
1188
1189
1189
1190
1191
1192
1193
1194
1195
1196
1197
1198
1199
1199
1200
1201
1202
1203
1204
1205
1206
1207
1208
1209
1209
1210
1211
1212
1213
1214
1215
1216
1217
1218
1219
1219
1220
1221
1222
1223
1224
1225
1226
1227
1228
1229
1229
1230
1231
1232
1233
1234
1235
1236
1237
1238
1239
1239
1240
1241
1242
1243
1244
1245
1246
1247
1248
1249
1249
1250
1251
1252
1253
1254
1255
1256
1257
1258
1259
1259
1260
1261
1262
1263
1264
1265
1266
1267
1268
1269
1269
1270
1271
1272
1273
1274
1275
1276
1277
1278
1279
1279
1280
1281
1282
1283
1284
1285
1286
1287
1288
1289
1289
1290
1291
1292
1293
1294
1295
1296
1297
1298
1299
1299
1300
1301
1302
1303
1304
1305
1306
1307
1308
1309
1309
1310
1311
1312
1313
1314
1315
1316
1317
1318
1319
1319
1320
1321
1322
1323
1324
1325
1326
1327
1328
1329
1329
1330
1331
1332
1333
1334
1335
1336
1337
1338
1339
1339
1340
1341
1342
1343
1344
1345
1346
1347
1348
1349
1349
1350
1351
1352
1353
1354
1355
1356
1357
1358
1359
1359
1360
1361
1362
1363
1364
1365
1366
1367
1368
1369
1369
1370
1371
1372
1373
1374
1375
1376
1377
1378
1379
1379
1380
1381
1382
1383
1384
1385
1386
1387
1388
1389
1389
1390
1391
1392
1393
1394
1395
1396
1397
1398
1399
1399
1400
1401
1402
1403
1404
1405
1406
1407
1408
1409
1409
1410
1411
1412
1413
1414
1415
1416
1417
1418
1419
1419
1420
1421
1422
1423
1424
1425
1426
1427
1428
1429
1429
1430
1431
1432
1433
1434
1435
1436
1437
1438
1439
1439
1440
1441
1442
1443
1444
1445
1446
1447
1448
1449
1449
1450
1451
1452
1453
1454
1455
1456
1457
1458
1459
1459
1460
1461
1462
1463
1464
1465
1466
1467
1468
1469
1469
1470
1471
1472
1473
1474
1475
1476
1477
1478
1479
1479
1480
1481
1482
1483
1484
1485
1486
1487
1488
1489
1489
1490
1491
1492
1493
1494
1495
1496
1497
1498
1499
1499
1500
1501
1502
1503
1504
1505
1506
1507
1508
1509
1509
1510
1511
1512
1513
1514
1515
1516
1517
1518
1519
1519
1520
1521
1522
1523
1524
1525
1526
1527
1528
1529
1529
1530
1531
1532
1533
1534
1535
1536
1537
1538
1539
1539
1540
1541
1542
1543
1544
1545
1546
1547
1548
1549
1549
1550
1551
1552
1553
1554
1555
1556
1557
1558
1559
1559
1560
1561
1562
1563
1564
1565
1566
1567
1568
1569
1569
1570
1571
1572
1573
1574
1575
1576
1577
1578
1579
1579
1580
1581
1582
1583
1584
1585
1586
1587
1588
1589
1589
1590
1591
1592
1593
1594
1595
1596
1597
1598
1599
1599
1600
1601
1602
1603
1604
1605
1606
1607
1608
1609
1609
1610
1611
1612
1613
1614
1615
1616
1617
1618
1619
1619
1620
1621
1622
1623
1624
1625
1626
1627
1628
1629
1629
1630
1631
1632
1633
1634
1635
1636
1637
1638
1639
1639
1640
1641
1642
1643
1644
1645
1646
1647
1648
1649
1649
1650
1651
1652
1653
1654
1655
1656
1657
1658
1659
1659
1660
1661
1662
1663
1664
1665
1666
1667
1668
1669
1669
1670
1671
1672
1673
1674
1675
1676
1677
1678
1679
1679
1680
1681
1682
1683
1684
1685
1686
1687
1688
1689
1689
1690
1691
1692
1693
1694
1695
1696
1697
1698
1699
1699
1700
1701
1702
1703
1704
1705
1706
1707
1708
1709
1709
1710
1711
1712
1713
1714
1715
1716
1717
1718
1719
1719
1720
1721
1722
1723
1724
1725
1726
1727
1728
1729
1729
1730
1731
1732
1733
1734
1735
1736
1737
1738
1739
1739
1740
1741
1742
1743
1744
1745
1746
1747
1748
1749
1749
1750
1751
1752
1753
1754
1755
1756
1757
1758
1759
1759
1760
1761
1762
1763
1764
1765
1766
1767
1768
1769
1769
1770
1771
1772
1773
1774
1775
1776
1777
1778
1779
1779
1780
1781
1782
1783
1784
1785
1786
1787
1788
1789
1789
1790
1791
1792
1793
1794
1795
1796
1797
1798
1799
1799
1800
1801
1802
1803
1804
1805
1806
1807
1808
1809
1809
1810
1811
1812
1813
1814
1815
1816
1817
1818
1819
1819
1820
1821
1822
1823
1824
1825
1826
1827
1828
1829
1829
1830
1831
1832
1833
1834
1835
1836
1837
1838
1839
1839
1840
1841
1842
1843
1844
1845
1846
1847
1848
1849
1849
1850
1851
1852
1853
1854
1855
1856
1857
1858
1859
1859
1860
1861
1862
1863
1864
1865
1866
1867
1868
1869
1869
1870
1871
1872
1873
1874
1875
1876
1877
1878
1879
1879
1880
1881
1882
1883
1884
1885
1886
1887
1888
1889
1889
1890
1891
1892
1893
1894
1895
1896
1897
1898
1899
1899
1900
1901
1902
1903
1904
1905
1906
1907
1908
1909
1909
1910
1911
1912
1913
1914
1915
1916
1917
1918
1919
1919
1920
1921
1922
1923
1924
1925
1926
1927
1928
1929
1929
1930
1931
1932
1933
1934
1935
1936
1937
1938
1939
1939
1940
1941
19

With both the experimental and control groups the course of healing was uneventful. The blisters were essential, however, in the first week. After several days, feathers were again implanted and the effect of time on the implants was observed. As expected in the control group, the skin at the site of implantation was extremely tender but since the internal space was largely occupied where the membrane of skin was present, there was no surface tissue.

Where the mandibular rod of poly-ethylene had been used, at six weeks the overall structure of the rod was essentially unchanged but there were fissures developing on the surface and the cut ends which had been sharply defined were somewhat rounded. The rod was somewhat softened on the surface. There was a progressive decrease in the amount of erosion of the PGA rod surface but this erosion was never associated with softening or other adverse reactions. By the 24th week the axis of poly-glycolic acid was essentially digested and the bone now showed normal tissue architecture.

EXAMPLE 5

At a stable bone plate affixed with absorbable pins

Factors of the hind legs of rabbits were selected as described in Example 4. The cut ends were hemispherical and immobilized by use of an internal support made from a sheet of polyethylene held approximately 1/8 inch thick 1/4" wide and 1 inch long, shaped to conform generally to the bone by softening the plastic with heat and premolding it about a metal rod of suitable diameter. The premolded plate was centrally located over the cut bone and while held in position, small holes were drilled through the plate and completely through the bone with a 1/16 inch drill, two holes on each side of the bone break. Small PGA rods about 1/8 inch long and 1/16" body over 1/16 inch in diameter made by flattening rod of this diameter by pressing against a heated surface were driven through the holes in the PGA plate and completely through the bone to hold the plate in place. The still unhealed bone was reapproximated, the lower leg splinted and the animal was returned to their cages. Injuries were then weekly and animals were sacrificed at 3, 6, 12, 18 and 24 weeks intervals. The legs which had been operated on were carefully disected to determine the fate of the polyethylene and polymerized to determine the course of the reaction. At 3 weeks the polyethylene was still in the PGA support and was easily cut by a sharp break but a bone was visible. At 6 weeks the PGA support was still in place but the bone was not visible. At 12 weeks the PGA support was still in place but the bone was visible. At 18 weeks the PGA support was still in place but the bone was visible. At 24 weeks the PGA support was still in place but the bone was visible.

As the first step in the analysis of the data, the mean values of the variables were calculated for each of the four groups. The results are shown in Table 1.

What is the best way to learn English grammar?

In this example where the arterial procedures were to be used in rabbits, the lesions were only "soft" in character. The abdominal aorta was exposed by incision through

the ventral wall, two clamps separated by about 16 inches were placed on the abdomen and held just distal to the renal artery. The apparatus entirely. Both of the abdominal clamps between the clamps was dissected and a comparable length of proximal tubing made as described above was then in place. The clamps were removed, and the abdominal wall closed firmly until blood seepage had stopped. The abdominal wall then closed and the animal returned to its cage. Sacrifices were made at the end of 1, 3, 6, 12, and 16 weeks and the prothetic implant and the neighboring tissue was examined. After the first week

After 1 week the tissue was evaluated. At this time the pores of the prosthesis were filled with fibrin and some new cell growth was noticeable at the cut ends of the blood vessel. By three weeks the fibrin clots had been partially replaced by new cells which represented the initial development of a pseudo intimal lining even before the ends of the original vessel. The polytetraethylene filaments were still intact but were shown in sections of surface erosion on microscopic examination. By 6 weeks the pseudo intimal lining was complete. Blood vessels were beginning to develop in this tissue layer. Growth of cells was occurring through the pores of the prosthesis which were now substantially enlarged by the obvious dilatation in size of the LGA filaments which were no longer continuous. Shredding of the PGA filaments was evident but the complete development of the pseudo intima prevented the shards from entering the blood stream where they could represent foci for clot formation. By the twelfth week the PGA was essentially replaced by tissue elements which formed a well vascularized multicellular layer completely capturing the polytetraethylene filaments of the prosthesis. The picture at 18 weeks was similar to that at 12 weeks with more vascularization and better organization of the cells of the inner living and outer surface of the prosthesis. There was a conspicuous absence of any inflammatory response of abnormal tissue reaction. The absorption of the polytetraethylene filaments left a space in the fiber network to permit adequate cell growth and proper vascularization so that recovery of tissue did not develop.

So far as inspection permits, similar results appear to be obtained in lambs. Of course with humans, and larger animals proportionately sized prostheses must be used.

Welding:

0 1. A vertical prosthesis comprising non-absorbable filaments shaped as a low-profile reinforcing element, and nonabsorbable suture material and nonabsorbable filaments, in at least a part of the element, a structure comprising a plurality of polymeric elements, whereby an implantable, non-absorbable, low-profile reinforcing structure is

DePuy Mitek, Inc. v. Arthrex, Inc.

C.A. No. 04-12457 PBS

DMI000283

